Podcast appearances and mentions of sloan kettering

Episode Overview: Dive into a thought-provoking episode where we explore the intricacies of the immune system, innovative natural remedies, and pressing global events. This episode is not just about the science of immunity but also touches on geopolitical tensions that are reshaping our world. Key Topics Discussed: 1. The Science and Efficacy of Coriolis Versicolor: Discover how this all-natural supplement is revolutionizing immune support for both humans and pets, as highlighted by over 400 studies from renowned institutions like Sloan-Kettering and Harvard University. 2. Predictive Programming – Fact or Fiction? The Supertramp Mystery: Unveil the eerie coincidences from historical media that hint at future events, exemplified by the symbolism in the 1979 Supertramp album "Breakfast in America." 3. Bioterror Threats and Global Repercussions: Analyze the recent revelations from Dr. David Martin about a possible forthcoming bioterror attack. How might this shape national security policies, and what are the implications for public health? Guest Appearance: Listen to insights from esteemed figures like Stephen Miller, who sheds light on the challenges in healthcare policies, and hear from Jeff, an advocate for natural immunological solutions effective against severe diseases. What to Expect: This episode offers a critical examination of contemporary issues, urging listeners to be informed and vigilant. With discussions ranging from immunity to looming geopolitical changes, it aims to empower the audience with knowledge to navigate these complex times. Call to Action: Stay proactive in safeguarding your health and communities. Consider immunity-boosting strategies from trusted sources and remain aware of unfolding global events that could impact your daily lives. Visit the recommended resources for more information. Thank you for Listening to Right on Radio. https://linktr.ee/RightonRadio Prayerfully consider supporting Right on Radio. Click Here for all links, Right on Community ROC, Podcast web links, Freebies, Products (healing mushrooms, EMP Protection) Social media, courses and more... https://linktr.ee/RightonRadio Live Right in the Real World! We talk God and Politics, Faith Based Broadcast News, views, Opinions and Attitudes We are Your News Now. Keep the Faith Here is the link to the document referenced. //efaidnbmnnnibpcajpcglclefindmkaj/https://biodefensecommission.org/wp-content/uploads/2024/05/National-Blueprint-for-Biodefense-2024_final_.pdf

What if your back pain is more than just physical? Dr. Stephen Thorp, MD — also known as “The Back Doctor” — joins The Council of Dude to explore spine health, performance, recovery, and the deeper messages our bodies send us when we're out of alignment. Stephen is a double board-certified, fellowship-trained physician who studied at Yale, Weill Cornell, HSS, and Sloan Kettering. He currently practices in Westchester County, NY, helping athletes and everyday folks move and live better. This one's about posture, pain, and purpose. Don't miss it.

Upper West Side, Mughlai Indian restaurant, Eagle Court, 84th between Broadway and Amsterdam, Alana and Daryl love Indian food, John Scully and Daryl played cribbage in college, Cribbage simply a card game, Board is just a scoreboard, Milo loved cribbage, Maybe a thousand games of cribbage with Milo, Milo liked sports video games, FIFA, Madden, NBA2K, Milo preferred a board game, Catan, Better strategist would win more often over time, Over time Milo would beat me more often than I would beat him, Video games don't require strategy the same way, Cards were always interesting to Milo, Probability and statistics, Card games quiet, Meditative component, With the Nachsins in Ocean City, Monopoly with the Nachsins, Milo and Daryl played cribbage, Milo never declined to play, Cribbage sounds like bridge, but is very simple, Milo and Daryl played at Sloan Kettering regularly, A few nurses at Sloan Kettering like cribbage, Brant Sistrom, Father and dear friend Milo died one after the other, Brant, like Milo, loved cribbage and Catan, Daryl and Brant have played cribbage together, Daryl warns Brant that he's gunning for him, Daryl invites others to play cribbage and to come to him for instruction, Great tribute to Milo, The Idea of Machines

Aight, listen up, fam! We're back in the mix with another banger. Today, we got the homie Sloan from the Sucio Boyz Podcast rollin' through. Here's what we're choppin' it up about:✅ Rumors & News✅ #RawOnNetflix✅ #VengeanceDay Recap✅ #AEW Grandslam Recap✅ #Smackdown Fallout✅ #TNA

BELIEVING IN HOPE WITHOUT COMPROMISE. Dr Virgilio Sacchini is dedicated to caring for people with breast cancer at the Memorial Sloan Kettering Cancer Center in New York. He originally trained at Universita degli Studi di Milano (UNIMI, Milan, Italy) where he is Professor of Surgery, and cooperates with the European Institute of Oncology in Milan (IEO, Milan, Italy). Dr Sacchini is a 2023 and 2024 Castle Connolly America's Top Doctor, the peer nominated group of the top 7% of all US practicing physicians. His goal is to achieve the best possible cancer outcomes and cosmetic results for his patients. “The new concept is to target only cancer cells.” “To cure someone and give him or her a miserable life is terrible, so the target in this moment is both better survival and better quality of life, less side effects.” “Once we prove that the combination of the medication with the Avacta technique works, of course it is approved and you can be cured everywhere in the world.”

For many, running just one marathon is a life goal and puts you in a category with only .01% of the global population who even attempt this feat each year. But imagine running 111 marathons? Now we are talking about a very select group that has ever pulled off this rare achievement. Michael Kloepfer is one of those special individuals who runs not only for the pure joy of it but for the purpose of raising money to support cancer research at Sloan Kettering. Since he started running marathons in 1996 at age 42 through his most recent New York City marathon finish at age 70, Mike and his team have raised over 1 million dollars to help beat cancer through Sloan Kettering. He has run races all over the world and is a winner of the Abbott medal for completing all 6 world major marathons (and leads all Abbott medal winners with 77 total finishes). He has now run 28 consecutive NYC marathons and is one of 108 people with active streaks over 25 for the Boston Marathon. Of course, any achievement like this doesn't come without challenges which for Mike has included fighting his own cancer in 2024. He has received surgery, is in complete response (successful removal), and is ready to keep going in 2025! Every step is that much more meaningful for Mike now as he continues to make a difference by assisting other patients in need. If you'd like to contribute and help Mike reach his $200k goal (he has already personally raised $100k), go to fredsteam.org and either enter Mike Kloepfer or his team name, Mikey's team. Enjoy this inspirational podcast and listen to the many stories Mike shares about his adventures and people he has met along the way including Grete Waitz, Dr. Howard Scher, and Aubrey Barr (video link tells her story). A word of caution, Mike's story has inspired many, so know by listening to this podcast you may find yourself thinking about joining the marathon craze and running the NYC streets with Mike raising money for Sloan Kettering!  You can listen here or watch here.

In episode 81 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Betsy Beggs of Goldman Sachs. At 23 years old, Betsy was a young professional finding her footing in New York City when she was blindsided by a stage 4 ALK+ lung cancer diagnosis. Tune in as she bravely shares her cancer story. For more, listen to Sarah Beggs, Betsy's mother, share her story from a parent perspective: youtu.be/05CrU4ltf80

Being in business is not just about tracking the financial health of your enterprise. It is about having a mission worth engaging, a kind of fire in the belly that fuels you through the difficult parts, and a sense for working at the edge of your capacity.Having a business and all that goes with it, it gives you the opportunity to grow into potentials you can only dream about in the middle of a difficult night.Our guest in this History Series conversation, Bill Egloff has been helping patients and practitioners for a long time with the products and services he's provided over the years. He's got a keen eye for business, regulatory details, and working with seemingly competing interests. It's a long road from running a natural foods store to collaborating with Sloan Kettering on cancer patients.As with the other history series pioneers, there have been some interesting forks in the road worth taking.

Join Journal Club Download my free guide to Internal Bleaching PDF Follow @dental_digest_podcast Instagram Connect on Instagram: @dr.melissa_seibert on Instagram DOT - Use the Code DENTALDIGEST for 10% off In the corridors of academia, Jed Best, DDS, MS (ADL '72, DEN '79) has emerged as a luminary whose passion for science and technology has remained steadfast, guiding his path through the ever-evolving landscape of dentistry. Armed with a BA in psychology from CWRU, Dr. Best was pursuing PhD programs in neuroscience when CWRU extended an invitation to its dental school, altering the trajectory of his journey. Yet, even amidst the transition, his dedication to the pursuit of knowledge remained unwavering and he has emerged as an authority in the world of dental technology and materials. Most recently, Dr. Best was interviewed in the March 2024 issue of Inside Dentistry regarding the benefits of glass ionomer over other dental restorative materials. After earning his Master of Science in Pediatric Dentistry from the University of Minnesota, Dr. Best turned down a faculty position at CWRU to follow his then girlfriend and now wife, Wendy Freedman, Esq. (WRC '73) to her work in New York City. Since then, Dr. Best has been a part-time faculty member at Columbia University for 45 years and served as the pediatric dentist at Sloan Kettering for 12 years where he specialized in treating bone marrow transplant patients. Dr. Best ran his own pediatric practice for 41 years and has served as a past OCE examiner for the American Board. Presently, Dr. Best is one of the section editors of the Journal of Pediatric Dentistry and holds academic appointments at Columbia University College of Dental Medicine and the University of Alabama at Birmingham School of Dentistry. At the invitation of Dr. Gerald Ferretti, Dr. Best has also been serving his alma mater as a Clinical Professor at Case Western Reserve School of Dental Medicine since 2011.  Dr. Best is board certified in Pediatric Dentistry and is a Past President of the College of Diplomates of the American Board of Pediatric Dentistry and Past Chairman of the Foundation of the College of Diplomates. His multifaceted contributions to the field have earned him recognition as a Fellow in the American Academy of Pediatric Dentistry and both the International and American College of Dentists. Amidst the achievements, Dr. Best remains grounded, attributing his success to the mentors and peers who shaped his journey. He expresses gratitude to former Dean Thomas DeMarco, Dr. John Gerstenmaier, Dr. Larry Fox and of course, current Dean Dr. Kenneth Chance. As a student, Dr. Best said he was always able to talk to the Dean and other department chairs whenever he needed to, and the Dean and the school supported his effort to attempt both a masters in biomedical engineering and a doctor of dental surgery degree at the same time. Dr. Best's commitment to giving back to his alma mater echoes the spirit of gratitude and camaraderie that defined his formative years. Dr. Best says of his class, “We had so much fun in dental school. That's why I come back to teach and support the school. I don't think students at other schools had as much fun. And I always feel appreciated here.” In addition to Dr. Best's expertise in glass ionomers, he has much to share about the use of AI in caries diagnosis, the dangers of blue light, and the potential hazards of air-powered instruments. In the labyrinth of innovation, Dr. Best has become a well regarded and sought after mentor and coach guiding the next generation of dental professionals.

Many autoimmune neuromuscular disorders are reversible with prompt diagnosis and early treatment. Understanding the potential utility and limitations of antibody testing in each clinical setting is critical for practicing neurologists. In this episode, Teshamae Monteith, MD, FAAN speaks with Divyanshu Dubey, MD, FAAN, author of the article “Autoimmune Neuromuscular Disorders Associated With Neural Antibodies,” in the Continuum® August 2024 Autoimmune Neurology issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Dubey is an associate professor in the departments of neurology and laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Autoimmune Neuromuscular Disorders Associated With Neural Antibodies Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @Div_Dubey Transcript Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME.   Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. Today, I'm interviewing Dr Divyanshu Dubey about his article on autoimmune neuromuscular disorders associated with neural autoantibodies, which is part of the August 2024 Continuum issue on autoimmune neurology. Welcome to the podcast. How are you?   Dr Dubey: Hi, Dr Monteith. Thank you for inviting me to be a part of this podcast. I'm doing well.   Dr Monteith: Well, why don't you introduce yourself to the audience? And, call me Tesha.   Dr Dubey: I'm Divyanshu Dubey (please, call me Div). I'm one of the autoimmune neurology consultants here at Mayo Clinic Rochester. I'm an Associate Professor of neurology, as well as lab medicine and pathology. My responsibilities here are split - partly seeing patients (primarily patients with autoimmune disorders, including neuromuscular disorders), and then 50% of my time (or, actually, more than 50%), I spend in the lab, either doing research on these autoimmune disorders or reporting antibodies in a clinical setting for various antibody panels which Mayo's neuroimmunology lab offers.   Dr Monteith: That's a nice overlap of subspecialty area. How did you get into this work?   Dr Dubey: I think a lot of it was, sort of, by chance. Meeting the right people at the right time was the main, sort of, motivation for me. Initially, I trained in India for my medical school and didn't really got much exposed to autoimmune neurology in India. I think our primary concern in my training was sort of treating TB meningitis and cerebral malaria - that was my exposure to neurology, including stroke and some epilepsy cases. As a part of application for USMLEs and coming here to residency, I did some externships, and one of the externships was at Memorial Sloan Kettering Cancer Center, and that's when I worked a few weeks with Dr Posner and got introduced to the idea of paraneoplastic neurological syndrome working with him. And that sort of started - I wouldn't call it vicious cycle - but my interest in the area of autoimmune neurology and paraneoplastic neurological disorders, which subsequently was refined further through residency and fellowships.   Dr Monteith: That's interesting. I actually rotated through - I did a externship also at Sloan Kettering, and I had a clinic with Dr Posner. And I thought, at the time, he was such a rock star, and, like, I took a picture with him, and I think he thought it was insane. And I didn't go into autoimmune neurology. So, you know, interesting pathways, right?   Dr Dubey: Yes. And I think he's inspired many, many people, and sort of trained a lot of them as well.   Dr Monteith: So, why don't you tell us what you set out to do when writing this article?   Dr Dubey: So, I think, given my background and training in various subspecialties in neurology, I was, sort of, formally did fellowships in autoimmune neurology, as well as neuromuscular medicine. One of the areas in these areas that I focus on is in my clinical practice, as well as in my sort of lab work, is autoimmune muscular disorders - and that to, specifically, autoantibodies and their clinical utility for autoimmune muscular disorders. So, that's what I wanted to focus on in an article. When I was invited to write an article on autoimmune muscular conditions in general, I thought it was very difficult to pack it all in one chapter or one article, so I narrowed my focus (or tilted my focus) towards antibody-positive disorders and trying to understand how we as neurologists can firstly sort of identify these conditions (which may end up being antibody-positive) – and then, on the other hand, once we get these antibody results, how we can find the utility in them or find them useful in taking care of our patients. At the same time, I also wanted to kind of highlight that these antibodies are not perfect, they do have certain limitations – so, that's another thing I sort of highlighted in the article.   Dr Monteith: So, why don't we just start with a very broad question - what do you believe the role of autoantibodies is in the workup of neuropathies and then neuromuscular disorders? Obviously, when we think of myasthenia gravis, but there are some presentations that you may not necessarily think to first order autoantibody tests. So, what is the role, and where does it fit in the paradigm?   Dr Dubey: I think it's extremely crucial, and it's evolving as time goes on, and it's becoming more and more clinically relevant. Let's say three, four decades ago, the number of biomarkers which were available were very limited and only a handful - and there has been a significant increase in these biomarkers with growing utilization of newer techniques for discovery of antibodies, and more and more people jumping into this field trying to not only discover, but try and understand and validate these biomarkers (what they truly, clinically mean). These antibodies, like you pointed out, ones for myasthenia (such as acetylcholine receptor-binding antibodies, or MuSK antibodies), they can be extremely helpful in clinical diagnosis of these patients. We all know the importance of EMG in managing our patients with neuromuscular disorders. But, oftentimes, EMG nerve conduction studies are often not available at every center. In those scenarios, if you have antibodies with very high clinical specificity, and you're seeing a patient on examination whom you're seeing ptosis (fatigable ptosis), double vision, you're suspecting myasthenia, you send antibodies, and they come back positive. It brings you closer to the answer that may, in turn, require you to refer to a patient to a place where you can get high-quality EMGs or high-quality care. In addition to getting to the diagnosis, it also, sometimes, leads you in directions to search for what is the trigger. A good example is all these paraneoplastic neurological syndromes (which we started our conversation with), where once you find a biomarker (such as anti-Hu antibodies or CRMP5 antibodies) in a patient with paraneoplastic neuropathies, it can direct the search for cancer. These are the patients where, specifically, these two antibodies, small-cell lung cancer is an important cancer to rule out - they require CT scans, and if those are negative, consider doing PET scan – so, we can remove the inciting factor in these cases. And then, lastly, it can guide treatment. Depending upon subtypes of antibodies or particular antibodies, it can give us some idea what is going to be the most effective treatment for these patients.   Dr Monteith: I think paraneoplastic syndromes are a very good example of how autoantibodies can help guide treatment. But, what other examples can you provide for us?   Dr Dubey: Yeah, so I think one of the relatively recent antibody tests which our lab started offering is biomarkers of autoimmune neuropathies - these are neurofascin and contactin, and those are great examples which can target or guide your treatment. I personally, in the past, have had many CIDP patients before we were offering these testings, where we used to kind of start these patients on IVIG. They had the typical electrodiagnostic features, which would qualify them for CIDP. They did not show any response. In many of these cases, we tried to do sort of clinical testing or sort of research-based testing for neurofascin and contactin back in the day, but we didn't have this resource where we can sort of send the blood, hopefully, and within a week, get an answer, whether these patients have autoimmune neuropathy or not. Having this resource now, in some of these cases, even before starting them on IVIG, knowing that test result can guide treatments, such as considering plasma exchange up front as a first-line therapy, followed by rituximab or B-cell depleting therapies, which have been shown to be extremely beneficial in these conditions. And it is not just limited to neurofascin or contactin (which are predominantly IgG4-mediated condition), but the same concept applies to other IgG4-mediated diseases, such as MuSK myasthenia, where having an antibody result can guide your treatment towards B-cell depleting therapies instead of sort of trying the typical regimen that you try for other myasthenia gravis patients.   Dr Monteith: And you mentioned where I was reading that, sometimes, nerve conduction studies and EMG can be useful to then narrow the autoantibody profiles. Oftentimes, in the inpatient service, we order the autoantibodies much faster, because it's sometimes harder to access EMG nerve conduction studies - but talk about that narrowing process.   Dr Dubey: Yeah. And it goes back to the point you just made where we end up sending, sort of, sometimes (and I'm guilty of this as well), where we just send antibodies incessantly, even knowing that this particular patient is not necessarily likely to be an autoimmune neurological disorder, and that can be a challenge, even if the false-positive rate for a particular test is, let's say 1% - if you send enough panels, you will get that false-positive result for a particular patient. And that can have significant effects on the patient - not only unnecessary testing or imaging (depending on what type of antibody it is), but also exposure to various immunotherapies or immunosuppressive therapies. It's important to recognize red flags – and that's one of the things I've focused on in this article, is talking about clinical, as well as electrodiagnostic, factors, which make us think that this might be an autoimmune condition, and then, subsequently, we should consider autoantibody testing. Otherwise, we can be in a situation - that 1% situation - where we may be sort of dealing with a false-positive result, rather than a true-positive result. In terms of EMGs, I think I find them extremely useful, specifically for neuropathies, distinguishing between demyelinating versus exonal, and then catering our antibody-ordering practices toward specific groups of antibodies which are associated with demyelinating neuropathies (if that's what the electrophysiology showed) versus if it's an exonal pathology (considering a different subset of antibodies) - and that's going to be extremely important.   Dr Monteith: You're already getting to my next question, which is what are some of the limitations of autoantibody testing? You mentioned the false-positivity rate - what other limitations are there?   Dr Dubey: So, I think the limitations are both for seropositive, as well as seronegative, patients. As a neurologist, when we see patients and send panels, we can be in a challenging situation in both of those scenarios. Firstly, thinking about seropositives - despite the growing literature about neurology and antibodies, we have to be aware, at least to some extent, about what methodologies are being utilized for these antibody tests. And what I mean by that is knowing when you're sending a sample to a particular lab, the methodology that they're utilizing - is that the most sensitive, specific way to test for certain antibodies? We've learned about this through some of the literature published regarding MOG and aquaporin-4, which has demonstrated that these antibodies, which we suspect are cell surface antibodies, not only generate false-positive, but also false-negative results if they are tested by Western blots or ELISAs. Similar can be applied to some of the cell surface antibodies we are investigating on the autoimmune neuromuscular side (we have some sort of unpublished data regarding that for neurofascin-155). Secondly, it's also kind of critical when you're getting these reports to kind of have a look at what type of secondary antibodies are being utilized, an example being we talked about neurofascin-155, and I mentioned these are IgG4-predominant diseases, so testing for neurofascin IgG4 and knowing that particular patient is positive IgG4 rather than neurofascin pan-IgG. That's an important discrimination, and important information for you to know, because we have seen, at least in my clinical practice, that patients who are positive for neurofascin IgG4 follow the typical story of autoimmune neuropathies - the ones who are not (who are just neurofascin-155 IgG-positive), oftentimes can have wide-ranging phenotypes. The same applies to neurofascin-155 IgMs. And then (not for all antibodies, but for some antibodies), titers are important. A good example of that is a3 ganglionic receptor antibodies, which we utilize for when we're taking care of patients who have autoimmune dysautonomia - and in these cases, if the titers of the antibodies are below .2 nmol/L, usually, those don't have a high specificity for AAG diagnosis. So, I get referred a lot of patients with very low titers of a3 ganglionic receptor antibodies, where the clinical picture does not at all look like autoimmune autonomic ganglionopathy. So, that's another thing to potentially keep in mind. And then, on the seronegative front, it's important to recognize that we are still sort of seeing the tip of the iceberg as far as these antibodies or biomarkers are concerned, specifically for certain phenotypes, such as CIDP. If you look at the literature, depending upon what demographics we're looking at or sort of racial profiles we're looking at, the frequency of these autoimmune neuropathy biomarkers range from 5% to 20%, with much higher frequency in Asian patients - so, a good chunk of these diseases are still seronegative. In the scenario where you have a very high suspicion for an autoimmune neuromuscular disorder (specifically, we'll talk about neuropathies, because that's why we utilize tissue immunofluorescence staining on neural tissues), I recommend people to potentially touch base with that tertiary care lab or that referral lab to see if they have come across some research-based antibodies which are not clinically validated, which can give you some idea, some additional supportive idea, that what you're dealing with is an autoimmune neuromuscular disorder. So, we have to keep the limitations of some of these antibody panels and antibody tests in mind for both positive, as well as negative, results.   Dr Monteith: So, you've already given us a lot of good stuff, um, about titer seronegativity and false-positive rates. And, you know, also looking at the clinical picture when ordering these tests, utilizing EMG nerve conduction studies, give us a major key point that we can't not get when reading your article.   Dr Dubey: I think the major key point is we are neurologists first and serologists later. Most of these patients, we have to kind of evaluate them clinically and convince ourselves at least partly that this might be an autoimmune neuromuscular disorder before sending off these panels. Also, I find it useful to narrow down the phenotype, let's say, in a particular neuropathy or a muscle disease or a hyperexcitability syndrome. So, I have a core group of antigens, autoantigens, or autoantibodies, which I'm expecting and making myself aware of - things beyond that will raise my antenna - potentially, is this truly relevant? Could this be potentially false-positive? So, clinical characterization up front, phenotypic characterization upfront, and then utilizing those antibody results to support our clinical decision-making and therapeutic decision-making is what I've tried to express in this article.   Dr Monteith: And what is something that you wish you knew much earlier in your career?   Dr Dubey: It's a very challenging field, and it's a rapidly evolving field where we learn many things nearly every year, and, sometimes, we learn things that were previously said were incorrect, and we need to kind of work on them. A good example of that is initial reports of voltage-gated potassium-channel antibodies. So, back in the day when I was actually in my medical school and (subsequently) in my residency, voltage-gated potassium-channel antibodies were closely associated with autoimmune neuromyotonia, or autoimmune peripheral hyperexcitability syndromes. Now, over time, we've recognized that only the patients who are positive for LGI1 or CASPR2 are the ones who truly have autoimmune neuromuscular disorders or even CNS disorders. The voltage-gated potassium-channel antibody by itself, without LGI1 or CASPR2, truly doesn't have a very high specificity for neurological autoimmunity. So, that's one example of how even things which were published were considered critical thinking or critical knowledge in our field of autoimmune neuromuscular disorders has evolved and has sort of changed over time. And, again, the new antibodies are another area where nearly every year, something new pops up - not everything truly stands a test of time, but this keeps us on our toes.   Dr Monteith: And what's something that a patient taught you?   Dr Dubey: I think one of the things with every patient interaction I recognize is being an autoimmune neurologist, we tend to focus a lot on firstly, diagnosis, and secondly, immunotherapy - but what I've realized is symptomatic and functional care beyond immunotherapy in these patients who have autoimmune neurological disorders is as important, if not more important. That includes care of patients, involving our colleagues from physical medicine and rehab in terms of exercise regimen for these patients as we do immunotherapies, potentially getting a plan for management of associated pain, and many other factors and many other symptoms that these patients have to deal with secondary to these autoimmune neurological conditions.   Dr Monteith: I think that's really well said, because we get excited about getting the diagnosis and then getting the treatment, but that long-term trajectory and quality of life is really what patients are seeking.   Dr Dubey: Yeah, and as you pointed out, most of the time, especially when we are in inpatient service, or even when we're seeing the patients upfront outpatient, we are seeing them, sometimes, in their acute phase or at their disease not there. What we also have to realize is, what are the implications of these autoimmune neurological conditions in the long term or five years down the line? And that's one of the questions patients often ask me and how this can impact them even when the active immune phase has subsided - and that's something we are actively trying to learn about.   Dr Monteith: So, tell me something you're really excited about in your field.   Dr Dubey: I think, firstly (which is pretty much the topic of my entire article), is novel antibodies and new biomarker discoveries. That's very exciting - we are actively, ourselves, involved in the space. The second thing is better mechanistic understanding of how these antibodies cause diseases, so we can not only understand diseases, we can also try and understand how to target and treat these diseases - this is being actively done for various disorders. One of the disorders which continue to remain a challenge are T-cell mediated diseases, where these antibodies are just red flags or biomarkers are not causing the disease, but it's potentially the T-cells possibly attacking the same antigen which are causing disease process, and those are often the more refractory and harder-to-treat conditions. I'm hoping that with some of the work done in other fields (such as rheumatology or endocrinology for type one diabetes), we're able to learn and apply the same in the field of autoimmune neurology and autoimmune neuromuscular medicine. And then, the final frontier is developing therapies which are antigen specific, where you have discovered that somebody has a particular antibody, and if that antibody is pathogenic, can I just deplete that antibody, not necessarily pan-depleting the immune system. And there is some translational data, there's some animal model data in that area, which I find very exciting, will be extremely helpful for many of my patients.   Dr Monteith: So, very personalized targeted therapies?   Dr Dubey: Correct. Without having all the side effects we all have to kind of take care of in our patients when we start them on, let's say, cyclophosphamide, or some of these really, really, significantly suppressive immunosuppressive medications.   Dr Monteith: Well, thank you so much. I learned a lot from reading your article to prepare for this interview, but also just from talking to you. And it's clear that you're very passionate about what you do and very knowledgeable as well, so, thank you so much.   Dr Dubey: Thank you so much. Thank you for inviting me to do this. And thank you for inviting me to contribute the article.   Dr Monteith: Today, I've been interviewing Dr Divyanshu Dubey, whose article on autoimmune neuromuscular disorders associated with neural autoantibodies appears in the most recent issue of Continuum on autoimmune neurology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining us today.   Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information, important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at Continpub.com/AudioCME. Thank you for listening to Continuum Audio.

In episode 76 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah travel to Indiana University in Bloomington to visit Sarah Beggs, Senior Vice President at the Indiana University Foundation. Tune in as Sarah shares how cancer became personal for her family as her daughter faced a stage 4 ALK+ lung cancer diagnosis.

Laura Raffa is a licensed creative arts therapist, with board certification in dance/movement therapy and a certified group psychotherapist. She is also a certified authentic movement practitioner and has facilitated authentic movement groups in private practice as well supervised several dance/movement therapy interns. She is also a crisis intervention trainer. Laura began her career treating patients through dance/movement therapy during a graduate school internship on Bellevue Hospital Prison Ward in 2005. She has experience working with children afflicted with cancer, patients with autistic spectrum disorder, and forensic patients through her work at Sloan Kettering, Montefiore Hospital, and Bellevue Hospital. Laura began her work on Rikers Island in 2014 on a grant to treat mentally ill patients requiring frequent re-hospitalization to the psychiatric service at Bellevue. Currently, Laura is the Director of Trainings and Treatment Aid Services at Rikers Island. She designs, teaches, and implements trainings for both health and custody staff, facilities staff support and team building groups, consults with clinical teams on challenging patient cases, and supervise staff to implement group programming and clinical engagement on the therapeutic housing units for incarcerated people at Rikers Island.   Laura's email: lraffa@pm.me   Reverence for Impulse is an unscripted, unplanned and (hopefully) unedited podcast with me, Weena Pauly-Tarr. Together with my guests, we're asking what is alive in this moment?We start each episode with a few minutes of meeting each other head-to-toe, through the language of our bodies, before we press record and bring it to a conversation. We start where we are. This is not a hard hitting agenda or getting to the bottom of things, it's about being in the bottoms of things. Finding each other in the not-knowing. I'm here for the spaciousness, the awkwardness, the silliness, the silence — From the dark insides of our bodies to the brightness of our minds, I'm excited to welcome people who's impulses I'd like to get to know. Website: weenapauly.com Instagram: weenapaulytarr

Don't be made at Coach Prime for ruining the story ... and possibly the entire evening.Regardless of if it happened or not, the fact we cannot immediately refute the entire Colorado football team being forced to watch Shedeur Sanders open up for Lil Wayne against their will is the reason John Buhler and Cody Williams were put on Earth to make this podcast.In this Step Brothers-themed episode, the guys remembered some dudes with the help of Johnny Hopkins and Sloan Kettering. They also wanted some older coaches to stop being dinosaurs and get a job, as in kindly retire.Also, not only did they know that Cops didn't start until 4, but they definitely maybe might know a few things that are certainly going to happen this college football season.Buhler (Staff Writer, FanSided.com) and Williams (Senior Editor, FanSided.com) took the long way home on this extra special episode of False Start. Hopefully, this podcast sounds better than a belly full of white dog crap tastes.

UConn basketball coach Dan Hurley has decided to stay with the Huskies for another season. A halt to congestion pricing has left a $1 billion hole in the MTA's budget. New York could drop the Regents requirement to graduate high school. Hartford Healthcare and Sloan Kettering partner up. And two years after a fatal Connecticut fire, questions still remain.

In today's Beating Cancer Daily episode, Saranne explores humor's powerful impact on healing and resilience. Inspired by a poignant moment at the funeral of a notable figure from Sloan Kettering. Saranne introduces a playful yet profound exercise called "Fun Cancer Recall." As someone who has navigated the turbulent waters of Stage IV cancer, she invites listeners to gather and share the funniest, most heartwarming memories with their friends and family, demonstrating how laughter can be a beacon during the darkest times. Join Saranne as she guides you through setting up this joyful practice, ensuring every participant contributes and gains a treasure trove of laughter to brighten their healing journey. Engage, laugh, and maybe even surprise yourself with forgotten tales of joy.The #1 Rated Cancer Survivor Podcast, Beating Cancer Daily, is listened to in over 73 countries and has over 260 episodes! In 1999, Saranne launched The ComedyCures Foundation from her chemo chair with a "Chemo Comedy Party." Now cancer-free, she's dedicated her life to helping others find strength, courage, and laughter in their fight against cancer. As a healthcare thought leader, speaker, patient advocate, and health and happiness expert, Saranne's work has garnered recognition and support from prestigious organizations like the NIH/NCI, the United Nations, the World Health Organization, and numerous universities and cancer societies. Saranne's transformative strategies, research findings, fun, practical tips, and comic insights can be found in the "Beating Cancer Daily" podcast and the BCD Membership Circle, where she helps listeners navigate their treatment and survivorship with humor and resilience. Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org?By becoming a supporter of ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide. Choose your level of support:• Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annually Donate Herehttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJT We Share the Laughter with Beating Cancer Daily Podcast Do you love the podcast? Please share it with a friend and spread the laughter!  

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable chats with Dr. Philip Bergman, known for his work on the Canine Melanoma Vaccine, Oncept®. Dr. Bergman shares his journey from considering a career in dairy practitioner to becoming a key player in the field of veterinary oncology. He talks about his experiences with human cancer research centers, the challenges he faced introducing new cancer treatments in veterinary medicine, and the importance of mentorship. Dr. Bergman also discusses the potential of treatments like checkpoint inhibitors. Get a glimpse into the evolving world of veterinary oncology, the collaboration between human and animal health research, and the practical challenges of making advanced treatments accessible.  Note: This interview was recorded in November 2023. Since then, Dr. Bergman became the Director of Clinical Studies at Mars Veterinary Health, globally responsible for clinical studies.  Transcripts are available at https://www.imprimedicine.com/podcast. To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/personalized-prediction-profile. Music Credit: Hazy by Beat Mekanik

In episode 70 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Mike & Jamie Simek. Tune in as the couple shares the strength and courage they've gained in their longtime US Marine career, and how that applies today to Mike's colorectal cancer journey. “Having an appreciation for how short life is and knowing that every day is precious is important – it comes into play here as you fight through cancer, too.”

JCO PO author Dr. Eric Klein shares insights into his JCO PO article, “Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers” Host Dr. Rafeh Naqash and Dr. Klein discuss how a multi-cancer detection test may facilitate workup and stratification of cancer risk in symptomatic individuals. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.   Today, we are excited to be joined by Dr. Eric Klein, Emirates Professor and Chair at the Glickman Urological and Kidney Institute at the Cleveland Clinic Lerner College of Medicine. Dr. Klein is also a distinguished scientist at Grail and author of the JCO Precision Oncology article titled "Performance of a Cell-free DNA-based Multi-cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancer."   Our guest's disclosures will be linked in the transcript.  For the sake of our conversation today, we'll refer to each other using our first names. It's great to have you here today, Eric, and welcome to our podcast.  Dr. Eric Klein: Thanks, Rafeh. I'm happy to be here. Dr. Rafeh Naqash: So today, we're going to try to delve into this very interesting paper. We've had a couple of very interesting podcasts on liquid biopsies, or plan to have a few more. And this is a different aspect of liquid biopsy assessment, and the context here is early cancer detection. Now, the story as it starts, is based on the methylation profile of cancer. Can you tell us, for the sake of our listeners, as we have a very broad audience ranging from trainees to community academic oncologists, what do you understand by methylation profile on a cancer? Dr. Eric Klein: Sure. Happy to start with that. There are lots of cancer signals in the blood. Cancer cells secrete or otherwise supply the bloodstream with DNA that has methylation signals that are specific to cancer. That's a hallmark of cancer-specific mutations. You can look at chromosome fragments, you can look at proteins and mRNA and exosomes and that sort of thing. In Grail's development study, we focused on using methylation because that, as I mentioned, is a fundamental process. A fundamental property of cancer cells is altered methylation. And in our original development studies, that was the strongest signal, the one that allowed us to have the lowest limit of detection when cancer was present, and the one that allowed us to have the best predictive accuracy for the cancer signal origin. Some people think about that as predicting the tumor origin or the tumor type. And that's the basis of Grail's assay, a pan-cancer methylation profile. Dr. Rafeh Naqash: Excellent. And now to understand some of the methodology that you used here, before we go into the details because there's a lot of sensitivity and specificity obviously associated with any cancer detection test, and you want a high sensitivity and specificity. And the idea here is that this would help in triaging patients appropriately using this non-invasive tool. Could you tell us the patient population that you were trying to enroll in this study? And I think there is, again, background to other studies that you have done using the Grail test. Could you put that into context of this specific study?  Dr. Eric Klein: Sure. The population in this particular publication was from substudy 3 of a much bigger study called the Circulating Cell-free Genome Atlas, or CCGA. That was a discovery, refinement, and validation study of this methylation-based signal. And in total, all three substudies together was about 15,000 people, and it was a case-control study. About 10,000 of the individuals enrolled had cancer and about 5000 were not known to have cancer and served as controls. In the first part of the study, substudy 1 of CCGA, we simply asked the question: In individuals with known cancer, could we detect a methylation-based signal? And the answer was ‘yes'. The second question was: In patients not known to have cancer, did we not see a signal? And by and large, the answer was ‘yes'. The second substudy was a refinement and validation of the original methylation-based test. And then this study, what we refer to colloquially as CCGA3, or substudy 3 of CCGA, was the final validation that underlies the methylation assay that is currently on the market.   So, in CCGA3, we determined what the performance characteristics of this test were in a case-control fashion, and what we found, importantly, was that the specificity was very high, at 99.5%, which means the false-positive rate is only half a percent. We found that the overall sensitivity for detecting cancer varied by stage, but when you included all stages 1 to 4, the overall sensitivity for detecting known cancers was about 51%. We found that the ability of this methylation-based test to predict the correct cancer signal origin was right around 90%. And finally, the final performance characteristic was really important, which is the positive predictive value. So in individuals who had a positive signal detected, the positive predictive value was 43%, which compares very favorably to existing screening tests, all of which are below 10%.  That was the background, and the development there was focused on eventually developing a test that will screen the general population, the asymptomatic population, at risk for developing cancer. This is a subset of CCGA3, or the substudy 3 of CCGA, where we looked at the performance characteristics of this test in individuals who had symptoms that could possibly be due to cancer and individuals who had underlying medical conditions that could result in a false positive, and individuals in particular over age 65, because the risk of cancer goes up over age 65. Dr. Rafeh Naqash: Thank you for explaining that. So, again, going to some of the finer details in this study, you mentioned some very important numbers here, 99%, 63%, or something in that range for sensitivity and specificity. Could you explain a little more on that based on the cancer types? As you mentioned, stage 4, when I read the paper, has more true positives likely based on or related to how much cell-free DNA is released in the tumor. The tumor burden may be playing a role there. Could you explain that a little more for our listeners? Dr. Eric Klein: A cancer that sheds cell-free DNA into the bloodstream is more likely to be aggressive, and that's been shown in multiple different studies using multiple different platforms. And the reason for that is that the ability to shed cell-free DNA into the bloodstream goes along with biologic processes that we know are related to tumor aggressiveness. So that's a higher mitotic rate, it's neovascularization or the angiogenic switch, it's the ability to be an invasive cancer. And so the fact that you can detect cell-free DNA in the bloodstream implies some degree of biologic aggressiveness, which is not to say that tumors that shed cell-free DNA into the bloodstream are not curable. They are, in fact, curable at the same rate as cancers in people who are not tested for cell-free DNA. We know that for sure. It's just a signal that is there for us to exploit for the detection of cancers in asymptomatic individuals. And the hope is when we screen the general population, the general asymptomatic population for cancer, as we do with mammography and colonoscopy and PSA and so forth, that we can detect cancers at earlier stages, when they are far easier to cure. So I mentioned in CCGA3 that the overall sensitivity across all stages for detecting the presence of known cancers was 51%. That varied from about 16% for stage 1 cancers to 40% for stage 2 cancers to over 80 and 90% for stage 3 and 4 cancers. Dr. Rafeh Naqash: Right. And again, to provide more background to this, what we've come to understand gradually, as you mentioned, is that shedding is an important event in cancer trajectory. Do you think detection of cancers that are likely positive, driver mutation positive, have a lesser tendency to shed and maybe resulting in lesser tendency to earlier detection also, or is that not something that's true?  Dr. Eric Klein: No, I don't think it has anything to do with the presence of driver mutations. The methylation signal that we see is a reflection of the perturbation of methylation in normal cells. So normal cells turn genes on and off using methylation. That's well known. Cancer cells exploit that biologic process of methylation by - in a gross oversimplification, but in a way that makes it understandable - they use methylation to turn off all the genes that prevent cell growth and turn on all the genes that allow cells to proliferate and get all these other biologic properties that make them invasive and so forth. So it's really important to understand that the test that was used in this study and that was developed in CCGA3 measures a shared cancer signal across multiple different cancer types. In CCGA3, we were able to detect more than 50 different individual kinds of cancers. It's a shared cancer signal that is fundamental to the biology of cancers, not just a specific cancer, but cancers.  Dr. Rafeh Naqash: I see. I think what I was trying to say, basically was, when we do liquid biopsies in the regular standard of care clinic, and you're trying to assess VAFs or variant allele frequencies for a certain mutation, you tend to see some of these BRAFs or EGFRs that are very low VAF, and the data that I've seen is that you treat irrespective of the low VAF, if it's a driving mutation process. If your VAF is 0.1%, you still treat it with a targeted inhibitor. The context that I was trying to put into this is it all depends on shedding. So this liquid biopsy that we currently use, whether other platforms that are out there, if you're not shedding as much cell-free DNA or circulating tumor DNA, you're probably not going to catch that subclone or clone that is a driver. So, does that play a role in your test also? If you have, let's say, a lung cancer that is an EGFR stage 4, if the shedding is low, following a general conceptual context that these driver mutation-positive tumors do have less shedding in general than the non-driver mutation-positive, would you think that would somehow impact the detection using your test or your approach? Dr. Eric Klein: So, generically speaking, any test that looks for a cancer signal in blood is going to have a lower limit of detection. So there are analytic variables that make it such that, if you have extremely low levels of cell-free DNA or your other target shed into the blood, it's not going to be detected by the test. That's an analytical issue. Having said that, it's important to distinguish the fact that this test that we're developing isn't really a liquid biopsy. A liquid biopsy, really, if you think about it, is on patients who have known cancer, and you're doing a biopsy of the blood to determine if you can see a signal in the blood. This test has been developed to screen asymptomatic individuals who are at elevated risk of cancer, who actually may not have cancer. So we don't really view it as a liquid biopsy. But conceptually, you are correct that every test is going to have an analytical lower limit of detection so that not every tumor that sheds minuscule amounts of cell-free DNA will be detected. But that's not really relevant to this particular paper, I would say. It's not really relevant to the performance characteristics that we saw in this population. Dr. Rafeh Naqash: Understood. Thank you for differentiating the usual liquid biopsy approach that we use currently in the clinic, and this approach, which is meant more for detection in asymptomatic individuals.  Going to some of the results, could you highlight some of the interesting findings that you had in this paper as far as performance is concerned? Dr. Eric Klein: Sure. Let me put it in a clinical context because we were just discussing asymptomatic individuals. That's what the test is ultimately meant for - screening asymptomatic individuals. But a common problem in oncology is this: patients present to primary care physicians with vague or nonspecific symptoms. Someone with COPD, for example, who presents with a cough, the cough could be due to the COPD, but if they have an underlying lung cancer, the cough could also be due to the lung cancer. Or someone presents with GI symptoms, could be related to cancer, or it could be related to a whole host of other things. And so there is a challenge for primary care physicians to sort out who might have cancer and who does not, particularly if they present with vague symptoms. In fact, most cancer diagnoses in the United States and Great Britain are actually found by primary care providers.   In this paper, we looked retrospectively, after the fact, in CCGA3, the case-control study that we did, to see how this methylation-based test performed in individuals who had symptoms that could be associated with cancer, or could be due to cancer, or might not be, might be due to other things. What we found was that the performance characteristics were as good or better in this symptomatic population, where the physician is facing a diagnostic dilemma, as they were in the asymptomatic population. This is really important, specificity false negative rate across all the patients in the study was the same as it was in CCGA3. It was 99.5%. Again, the false positive rate was only 0.5%. We found, however, that overall sensitivity was better in the symptomatic population, and it was 64% instead of, or as compared to 43% in the asymptomatic population. That is not surprising because some patients who present with symptoms are more likely to have cancer.   We also looked at a subset of patients who had GI cancers because that's a very, very common presenting symptom in primary care practice, and this test performs exceptionally well for detecting GI cancers. We found that the overall sensitivity was 84%. Finally, and importantly, in terms of the clinical utility of a blood-based test to detect cancer and direct a diagnostic workup, what we call the clinical signal origin accuracy - the likelihood or prediction that a positive signal was related to a particular tumor type - overall accuracy in this population was 90%. So if you had a cancer signal detected and you had a clinical signal of origin assigned to it, let's say, the test came back with cancer signal detected, the CSO prediction was GI cancer, the overall accuracy in actually finding a GI cancer was 90%. Actually, it was a little higher for GI cancers, but overall, for all cancers, it was 90%. Dr. Rafeh Naqash: You mentioned that GI cancers had a very high sensitivity, around 84% or so. Is that, again, related to the tumor shedding compared to some other tumor types?  Dr. Eric Klein: Yes, there is a broad range of shedding across tumor types. So if you look at our data from CCGA, cancers like thyroid, prostate, and kidney do not shed a lot of cell-free DNA into the bloodstream, whereas GI cancers, hematologic malignancies, ovarian and pancreatic cancers shed much more cell-free DNA, and therefore their sensitivity for detection of those cancers is better.  Dr. Rafeh Naqash: What would be the alternate approach? Your sensitivity here is 64%, which is pretty good, but it's not perfect. So the patients who potentially would be missed using this test, what would be the alternate approach capturing those patients also and hopefully avoiding a missed cancer diagnosis?  Dr. Eric Klein: Well, it would be whatever the standard workup is that a primary care physician orders for someone who has vague symptoms. So, he idea here was to develop this, what we call a diagnostic aid for cancer detection in the symptomatic population. The idea here is to make the workups more efficient and to lend a greater degree of certainty as to what the diagnostic pathway ought to be. So, if you have a patient with vague symptoms and you're not sure if they are due to cancer or not, you might order a pretty broad diagnostic evaluation that might not end up finding cancer. In fact, if you take all the patients in a primary care setting, only about 7% of those individuals have cancer. Whereas, if you have a blood test that has a sensitivity of 64% and a positive predictive value of 75%, and you did that blood test early in the diagnostic workup and it was positive, you can do a much more tailored and perhaps a more efficient evaluation in speeding the diagnostic resolution.  Dr. Rafeh Naqash: As you mentioned, perhaps avoid unnecessary testing, which adds to the overall cost burden in the healthcare field.   Dr. Eric Klein: Correct. This was tested in another study called SYMPLIFY, which was done in a similar population of patients as this study - symptomatic patients presenting with vague symptoms or GI symptoms or weight loss, fatigue, those sorts of things, to primary care practice in the UK. And that was a prospective study. And the performance characteristics were very similar to what we saw in this study, although the overall positive predictive value in that study was 75% if you look at all cancers. And that would be very useful to a primary care physician and a patient to know what the likelihood of their having cancer is at the time they present or within a few days of presenting. Dr. Rafeh Naqash: Absolutely. And perhaps, to complement this approach with some of the other diagnostic approaches, maybe the possibility of detecting cancer earlier increases. So this is likely complementary and not necessarily the one-stop-shop. Dr. Eric Klein: It's important to understand that even in the symptomatic population, this is a screening test. And so, like all screening tests, if you have a positive mammogram that shows a nodule, you need to have a diagnostic workup to prove whether or not you have cancer. This blood test does not make the diagnosis of cancer; it simply helps direct a diagnostic evaluation that's necessary to confirm whether or not cancer is present or absent. That's true for both the asymptomatic and symptomatic populations. Dr. Rafeh Naqash: Could you tell us a little bit more about the CSO prediction in the general context of oncology and NGS, or the whole transcriptome sequencing that we do these days? We often see on a report that says,“What is the likely tumor of origin?” if you have an unclear primary. Can you explain that in the context of the approach that you guys use for CSO prediction? How does it differ from methylation versus mRNA prediction of tumor of origin or cell of origin?  Dr. Eric Klein: Methylation has a rich signal in it, and it can distinguish cancer cells from a non-cancer signal, and using a second algorithm, specific methylation patterns that are specific to given lineages can identify lung cancer versus colon cancer versus liver cancer.  Dr. Rafeh Naqash: Understood. Do you see this as becoming an approach that could be used, using, for example, urine or other sources that we can easily acquire versus blood? Dr. Eric Klein: Possibly. There is a lot of work in the field looking at urine-based markers for cancers, particularly, obviously, urologic cancers. And so there are already some products on the market made by other companies using methylation and other specific mutation patterns, for example, in urine to detect bladder cancer and to determine bladder cancer aggressiveness. It is an area of active investigation.  Dr. Rafeh Naqash: This is definitely an exciting field, and the way the entire field of liquid biopsies in general is moving as it's detecting cancers or identifying mutations, and then implementing appropriate approaches, whether it is more screening or more treatment and all the drugs, etc.  Are there any other interesting future approaches that you guys are planning as part of this paradigm shift that I envision will hopefully happen in the next few years?  Dr. Eric Klein: Yes, as a company, Grail is focused on using this methylation-based technology across the entire cancer spectrum. So that's screening asymptomatic individuals, it's helping to direct diagnostic workups in individuals who present with symptoms to primary care practice, and also in the post-diagnostic space and all the possible uses there. So the detection of minimal residual disease and the decision on whether or not additional treatment is necessary, predicting response to particular therapeutic agents, or even choosing the correct therapeutic agents. All of that is under development. Dr. Rafeh Naqash: Definitely exciting. Now, the last portion of this podcast is specifically meant to highlight your career and know a little bit more about you. Could you tell us about your career trajectory and how you shifted focus towards a biomarker-driven approach?  Dr. Eric Klein: Sure. Biomarkers have been a part of my career for a long time. I am trained as a urologic oncologist and did my residency in urology at the Cleveland Clinic and a fellowship at Sloan Kettering. At the dawn of the molecular biology era, the lab I worked in bought one of the very first PerkinElmer RT PCR machines for $5,000. It took up a whole desktop. I got very interested in genomic science at that time. So I spent well over 30 years practicing urologic oncology at the Cleveland Clinic, primarily focusing on prostate cancer. In the course of my career, I had the opportunity to work on a number of blood-based, urine, and tissue-based biomarkers. I have always been interested in understanding how our ability to measure molecules in blood and urine can help improve patient outcomes either through a streamlined diagnostic process or understanding of the biology of the disease better, picking the appropriate therapy, and so forth.  In the course of that, I worked with someone at a company called Genomic Health in developing  a biopsy-based RT PCR gene expression assay that helped select men for active surveillance. That individual subsequently joined Grail and he came knocking on my door in 2016 when Grail was just getting started to tell me about this exciting new technology. He said, “This isn't about urologic cancers in particular, but would you be interested in helping us accrue patients for this big clinical trial we're doing, CCGA, and determine if this technology would be useful in some way in helping patients.” And being the curious individual that I am, I said, “Sure.” And so I helped accrue lots of patients to CCGA. The results were shared, and I was quite excited by them and continued to work with the company on other studies, including PATHFINDER and some others, and eventually became a consultant for them.  When I reached what I thought was the end of my clinical career by choice, I decided to step away from clinical practice, I had the opportunity to join Grail as a scientist, and that's where it's been. And what I would say, in the big picture, is this: as a surgeon, I was able to help a lot of patients on an individual basis. So I did about 10,000 major cancer operations in my career. So I helped those 10,000 people. As an academician, I was able to make certain observations and publish them in a way that taught people about different kinds of surgical techniques and how they may work better, and so I was able to expand my impact beyond the patients that I actually touched.  When I heard about and understood what Grail was trying to do, I thought, “Wow, if we could develop a screening test that detects lots of cancers that we don't screen for - about 70% of all cancer deaths in the US are from cancers that we have no screening tests for - and if the screening population in the United States, individuals between ages 50 and 79, that's how CMS defined screening populations, well over 100 million a year, if this works, think about the impact that that could have.” That is really why I got excited about it. It fit my scientific interest, and I could see the big picture.  Dr. Rafeh Naqash: Thank you for giving us some insights about your personal career. It is definitely a very interesting topic. I learned a lot, and hopefully, our listeners will find it equally interesting. Thank you again for being here today.  Dr. Eric Klein: My pleasure. Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to rate and review this podcast, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and inform. It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   The guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

Romain Kapadia is a known entrepreneur and investor who in addition to his private equity work and success is an active Owner/Operator at several leading Texas-based events companies, The Astorian and Jackson & Company.Recently, the young, high energy, driven, thoughtful, marathon running, Romain...found himself with a quite serious battle on his hands. The fight for his life and health. When Warren read Romain's Nov 2023 Facebook post sharing his intense and immediate battle with cancer...and while doing so - eloquently expressed himself in a way that brought comfort, confidence, and positivity for those that love him...we knew this was an important interview to have.   How Romain framed his thinking on what was at hand with love, grace, and "his silver linings" was profound.Romain shares how much of his drive and  strength comes from how he was raised...watching his parent's who moved here to the USA with no money...and worked their way up to provide a good life for Romain and his family. Thank you to Romain and his willingness to "go there" with us in this conversation.   And if you are curious about the post from Romain that moved us all? Here it is:Extended Family, Friends, Acquaintances, and fellow Revelers from around the world...As you know, I'm not one to share negative news but I want to update you on a recent health scare that I've had to deal with. My aim is to make this an uplifting and positive message.Since late 2020, I had been having a nagging running pain in my hip and have seen numerous doctors, undergone dozens of tests and months of PT to resolve  the issue, but it never completely went away. Finally in late summer 2023, after undergoing yet another scan and looking for a muscle tear, the doctors came back with a totally unexpected diagnosis..."YOU HAVE CANCER".Given all the efforts I put into my health and well-being, this was a complete shock. I visited the nation's top 2 hospitals to discuss diagnosis and treatment protocols, ultimately deciding to get treated at Sloan Kettering in NYC. I am eternally grateful to have been connected to Dr. Sam Singer (https://www.mskcc.org/cancer-care/doctors/samuel-singer), likely the top Sarcoma surgeon in the world.---On October 23rd, I underwent a 16 hour surgery, requiring 4 surgical teams, to remove a 13cm liposarcoma tumor in my pelvis. The first few days were very tough but thankfully, I've been recovering well and have now almost regained my entire range of motion.After 2 weeks, I was released from the hospital but was readmitted last Tuesday, after having severe abdominal pain and vomiting for 48 hours. This was related to digestive inflammation from surgery. I was fitted with a tube through my nose and throat into my stomach.  I wasn't able to eat or drink any water for 6 days...every time I swallowed it felt as if I had a bout of strep throat.The good news is, I've largely recovered and should hopefully be going home soon (again). The doctors are optimistic about me making a full recovery over the coming weeks and months.HERE'S THE SILVER LINING....Despite the trials and tribulations over the past 90 days, and despite some of the work that will be required to get back to 100%, I am eternally grateful for this diagnosis as it has enlightened me in ways not possible through the monotony of everyday routine, but only through overcoming life's toughest challenges. Here's some of what I've learned.1) YOU are your advocate (for all things in life). When a health problem arises, DO NOT give up until you have an answer. Doctors are great, but only you have the ability to persist to find solutions.2) YOU choose to be happy. Thankfully I've started down this path for the past several years, giving me the ability to see the positive and largely eliminate negative thoughts. This mental fortitude has been hugely beneficial in getting through the darkest days.3) YOU must live in the present. Enjoying the present moment relieves you from worrying about the future or regretting the past. All anxiety is driven from these thought patterns.4) DON'T waste time. We all face our own unique battles that arise unexpectedly at any time. Life is short, go for what you want and intentionally pursue the things you want with 100% conviction.5) FAMILY, FRIENDS and RELATIONSHIPS are the most important things in life. Frankly, it would have been impossible to go through this experience alone. I especially want to thank my immediate family, and close friends (you know who you are) who have shouldered my emotional roller coasters and been by my side every day. And, of course, my mom who's been my rock.---I know this will be a platform for me to live a more successful, fulfilled and happy life and I plan to utilize the lessons learned towards the rebuilding of myself into a better, stronger, wiser and more balanced Romain 2.0.I've already set a goal of running the NYC marathon in 2025 (my 14th race) and surfing later this year in El Salvador.Love you all and hope to reconnect with each and every one of you in the near future. I'll also share more updates soon.F**K CANCER,RomainPS - Apologies for the long post. If anyone is going through a similar situation, PLEASE REACH OUT.Find ROMAIN ON LINKEDIN BY CLICKING HEREFind WARREN SPIWAK on LINKED IN BY CLICKING HEREThe Astorian Website HERE

From the barbarism of terrorists to the pressure to adopt Sharia law, to warnings from American intel officials, this episode will hopefully break through your denial. It is only when enough of us realize the imminent danger that we're in, that people will do something to prevent global jihad. You know about the barbaric attack Hamas inflicted on Israel on October 7. Now you will hear two more examples of barbarism that go lower than terrorists beforethem. After killing and beheading an IDF soldier in Israel, a Hamas terrorist tried to sell his head in Gaza for $10,000,while Pro-Palestinian protesters terrorized cancer patients at Sloan Kettering Hospital in New York City. Terrorists' 1,000-year plan to take over the world and enact Sharia law has already begun. You will hear about schools in Germany and Britain, where students, from migrant families, originally from Radical Islamist countries, have acted like Sharia police, pressuring other Muslims and non-Muslims toobey Sharia law. Even Radical Islamic TikTok stars are  threatening Europe with violence if they don't obey. U.S. officials are warning that Hezbollah could strike America. Hear why they say this could be more of a threat than ISIS or AlQaeda. And finally, if you still doubt the virulence of terrorists, you will hear about the new website Israel has created with photos and videos of the October 7 Massacre. It starts with a warning and isn't for the faint-hearted, but it's proof of the atrocities that Hamas propaganda doesn't want you to believe. 

It's that time of year! Cranberries are in season! There's a good chance you'll sit down to some cranberry dishes or drinks during the holidays. Maybe this episode can be fodder for conversation? ("Yes, Uncle Frank, those pics are... something. That chicken nugget really does look like Elvis. A-hem, how about this cranberry sauce? Did you know... ")  In this holiday minisode, Tina & Leah chat about the history, the culinary, and the medicinal uses of cranberries. So, what are you waiting for? Hit that play button! And remember to give us a 5-star review.  :)   (We appreciate it!)26 ways to use a bag of cranberries (warning: not all of them are naturopath-approved)The Cranberry Blitzen Mocktail Recipe (by Leah!) The Festive Cranberry Shrub Leah mentions in the episodeOrange-cranberry, gluten-free biscotti recipe (by our former guest, Amy Rothenberg, ND)More technical info on cranberries and their effects:Sloan-Kettering review of cranberries as medicineReview of phytochemicals in cranberries (proanthocyanidins and such) Cranberries for Urinary Tract Infections(UTIs)- the latest Cochran Review (2023)The mechanism  of UTI preventionSupport the showWe hope you find our talks useful and entertaining! Share this podcast with someone you think would like it!https://www.thecancerpod.com Have an idea or question? Email us: thecancerpod@gmail.comJoin our growing community, we are @TheCancerPod on: Instagram Twitter Facebook LinkedIn We appreciate your support! THANK YOU!

We learn about pancreaticoduodenectomy (the Whipple) with Michael Cavnar (@DrMikeCavnar), surgical oncologist at University of Kentucky, with a fellowship in Complex General Surgical Oncology from Sloan Kettering. He specializes in GI surgical oncology (liver, pancreas, stomach, etc), with ongoing research in GI stromal tumors and hepatic artery infusion pump chemotherapy. Find us on Patreon here! … Continue reading "Episode 67: Whipples with Michael Cavnar"

Description: An immersive reading of Sassafras Tea by Effie Lee Newsome with reflection on tea rituals, herbal remedies, the good and hindsight. Website:https://anauscultation.wordpress.com/ Work:Sassafras TeaBy Effie Lee NewsomeThe sass'fras tea is red and clear In my white china cup, So pretty I keep peeping in Before I drink it up.I stir it with a silver spoon, And sometimes I just hold A little tea inside the spoon, Like it was lined with gold.It makes me hungry just to smell The nice hot sass'fras tea, And that's the one thing I really like That they say's good for me.References:Effie Lee Newsome: https://poets.org/poet/effie-lee-newsome  Sassafras Tea: https://poets.org/poem/sassafras-tea Caroling Dusk: https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1136&context=zeabook Noé, J. (2002). Chapter 10 Ethnomedicine of the cherokee: Historical and current applications. In Advances in Phytomedicine (Vol. 1, pp. 125-131). Elsevier B.V.Elizabeth A. Hausner, Robert H. Poppenga.  Editor(s): Michael E. Peterson, Patricia A. Talcott, (2013) Chapter 26 Hazards Associated with the Use of Herbal and Other Natural Products. In Small Animal Toxicology (Third Edition, pp 335-356) W.B. Saunders,Sloan Kettering: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/sassafrasHilton L, Hempel S, Ewing BA, Apaydin E, Xenakis L, Newberry S, Colaiaco B, Maher AR, Shanman RM, Sorbero ME, Maglione MA. Mindfulness Meditation for Chronic Pain: Systematic Review and Meta-analysis. Ann Behav Med. 2017 Apr;51(2):199-213. Rusch HL, Rosario M, Levison LM, Olivera A, Livingston WS, Wu T, Gill JM. The effect of mindfulness meditation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. Ann N Y Acad Sci. 2019 Jun;1445(1):5-16.Black DS, Slavich GM. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci. 2016 Jun;1373(1):13-24.Charlton A. Medicinal uses of tobacco in history. J R Soc Med. 2004 Jun;97(6):292-6.

We know that Hashem runs the world at large and our lives individually. We know that everything Hashem does is the absolute best for us. But somehow these concepts don't always register when we need them to. There are times when a person works very hard to achieve a certain goal; he makes all the necessary hishtadlut and hopes for the outcome he is anticipating. But if he doesn't get it, he becomes very disappointed. At those moments, it's very hard to truly take to heart that Hashem was controlling everything and did bring about the best possible outcome. It requires the person to pause and think about what is really happening, to bring the emunah that he already has to the forefront. If someone can do that, besides for the endless rewards he will receive for it, it will also help him to become much calmer and feel soothed. A woman who has had her share of difficulties told me the following story. Besides her battle with cancer which, baruch Hashem, she is doing very well with, she encountered a very big issue last year with her son in his yeshiva. Apparently, the rabbi that he had was not the best fit for him and over the course of the year the boy went down in many areas. The woman was doing her best to encourage him and help him stay afloat, but it was not a simple task. He needed various therapists and specialists to help him with all the problems he encountered. Although the rabbi was very good, his personality just did not fit with this boy's personality. Starting already from the second half of the year, the woman was addressing the issue of who the boy's rebbe would be the following year. After discussing it with people who knew, it was determined there was one rebbe that would be the perfect fit for him and hopefully be able to bring him back to the way he used to be. There were a couple of other rebbeim who would potentially be good for him and there were some that she was told to make sure to avoid. They were also great rebbes , just not for her son's personality. So she spent the second half of the year, as well as the summer, making meetings with all the different heads of the yeshiva, describing what she and her son went through and what was necessary to be done to correct it. She gave it 110% effort, not wanting to settle for anything but the best for her child. A week before yeshiva started, she asked what class her son was going to be in. She was told she would not be allowed to know that information until the first day of school. That day she had to be in Sloan-Kettering for a procedure and wouldn't be able to bring her son to the yeshiva. When the procedure ended that day, she immediately called the yeshiva to see who her son's rebbe was. They refused to tell her. When she finally got home that evening and her son arrived, she asked him which class he was in. She was shocked to find out that the one rebbe that she was told wouldn't be good for him was the one that he got. She was beside herself. How could this possibly have happened? She thought. She literally did everything in her power to avoid it. She called the school to try to switch the class but it wasn't an option. Her mind began racing with all the flashbacks of all the difficulties of the previous year and she became very nervous about what the future held. But then, she stopped herself. She took a breath and reached deep down and pulled out all the emunah she had gained over the years. She said to herself, This doesn't make any sense, but it doesn't have to. Hashem is the One who decided which class my son should be in. No people have any say other than Him. This is the class my son needs to be in, and therefore, I'm going to accept it with happiness. That night, she felt so calm, with a feeling she thought she could never have after what she had gone through the previous year. Baruch Hashem, it has been a month into the year now and her son is doing wonderfully with this rabbi. The woman's ability to pause and take a step back and recognize that only Hashem made that decision is truly inspiring. That is real emunah. It is a wondrous avodat Hashem and it also brings the person so much peace of mind.

El adenocarcinoma de páncreas es uno de los tumores más peligrosos. Este tipo de tumor supone la tercera causa principal de muerte por cáncer en los Estados Unidos y la séptima a nivel mundial. Por desgracia, su incidencia va en aumento, pero su tasa de supervivencia es pequeña, de solo el doce por ciento de los pacientes, una tasa que ha permanecido prácticamente invariable en los últimos sesenta años, y eso a pesar de los enormes avances realizados para tratar y curar otros tipos de cáncer. En este estado de cosas, investigadores del Instituto del Cáncer Sloan Kettering de Nueva York, tuvieron la idea de intentar utilizar la tecnología de las vacunas de ARN mensajero, similares a las que todos hemos recibido durante la pandemia de COVID-19, para estimular al sistema inmunitario de cada paciente con los nuevos antígenos que, por mutaciones al azar, ha ido generando su tumor particular. En un primer ensayo, estudiaron su eficacia en dieciséis pacientes de adenocarcinoma de páncreas y encontraron que la vacuna resulta eficaz en ocho de ellos. Es un buen comienzo.

El adenocarcinoma de páncreas es uno de los tumores más peligrosos. Este tipo de tumor supone la tercera causa principal de muerte por cáncer en los Estados Unidos y la séptima a nivel mundial. Por desgracia, su incidencia va en aumento, pero su tasa de supervivencia es pequeña, de solo el doce por ciento de los pacientes, una tasa que ha permanecido prácticamente invariable en los últimos sesenta años, y eso a pesar de los enormes avances realizados para tratar y curar otros tipos de cáncer. En este estado de cosas, investigadores del Instituto del Cáncer Sloan Kettering de Nueva York, tuvieron la idea de intentar utilizar la tecnología de las vacunas de ARN mensajero, similares a las que todos hemos recibido durante la pandemia de COVID-19, para estimular al sistema inmunitario de cada paciente con los nuevos antígenos que, por mutaciones al azar, ha ido generando su tumor particular. En un primer ensayo, estudiaron su eficacia en dieciséis pacientes de adenocarcinoma de páncreas y encontraron que la vacuna resulta eficaz en ocho de ellos. Es un buen comienzo.

Seg 1: Did you know that Surrey is one of the top up-and-coming culinary cities in the world? Guest: Raj Thandhi, Food Blogger and founder & editor of Pink Chai Livin Seg 2: The Weekly Cecchini Check-in Trump gets back on CNN, Santos indicted and Title 42 ends. Guest: Reggie Cecchini, Washington Correspondent for Global News Seg 3: In a recent development, the injunction application filed by five players of Simon Fraser University's football team has been denied by the B.C. Supreme Court. Guest: Joy Johnson, President of Simon Fraser University Seg 4: SFU football players' injunction rejected by B.C. Supreme Court Despite the denial of their injunction application, the determination to save the Simon Fraser University football team remains strong. Guest: Mark Bailey, President of the SFU Football Alumni Society Seg 5: Kickin' it with The Caps  Fresh off a dominating 4-1 victory against York United FC in Canadian Championship action Guest: Vanni Sartini, Coach of the Vancouver Whitecaps Seg 6: Extraordinary British Columbians: Dr. Imran Ratanshi Dr. Imran Ratanshi – Surrey Memorial Hospital. Dr. Ratanshi is a leading reconstructive craniofacial surgeon and microsurgeon. He literally reconstructs new faces for people. Came from Sloan Kettering and Harvard Medical school. Could have worked anywhere in the world but came home to Surrey because of his family roots. Guest: Dr. Imran Ratanshi, Reconstructive Microsurgeon and Craniofacial Reconstruction Surgeon at Surrey Memorial Hospital Learn more about your ad choices. Visit megaphone.fm/adchoices

Extraordinary British Columbians: Dr. Imran Ratanshi Dr. Imran Ratanshi – Surrey Memorial Hospital. Dr. Ratanshi is a leading reconstructive craniofacial surgeon and microsurgeon. He literally reconstructs new faces for people. Came from Sloan Kettering and Harvard Medical school. Could have worked anywhere in the world but came home to Surrey because of his family roots. Guest: Dr. Imran Ratanshi, Reconstructive Microsurgeon and Craniofacial Reconstruction Surgeon at Surrey Memorial Hospital Learn more about your ad choices. Visit megaphone.fm/adchoices

In this Episode of The Bourbon Life Podcast presented by VisitLEX, Matt and Mark spend some time hanging out with Dr. Nicole Saphier, Radiologist & Director of Breast Imaging at Sloan Kettering, Author, Speaker, and FOX News Contributor. They talk with Nicole about how she decided to become a Radiologist and the amazingly important work that she does in women's health at Sloan Kettering; her work with FOX News, initially as a medical contributor, and how she got that role; and her most recent book, Panic Attack, and what we've learned from the recent pandemic and how the past three years have affected us all. And since she's not a big Bourbon drinker it was a great opportunity for the guys to walk her through some great Bourbons, including Basil Hyden's, Bardstown Bourbon Company Origin Series Wheated Bottled in Bond, and the 2022 Pappy Van Winkle 15-Year Old. This Episode of The Bourbon Life Podcast is also sponsored by Liquor Barn, The Stave Restaurant, Three Chord Bourbon, and District 7 Social. Check out all of our amazing sponsors online at:  www.visitlex.com www.liquorbarn.com     www.thestavekentucky.com  www.threechordbourbon.com

The word “palliate” comes from the Medieval Latin “palliare,” meaning to conceal, or to cover with a cloak. In the context of health care, a palliative approach is one that alleviates symptoms without curing disease. In this episode of The ABMP Podcast, Kristin speaks with author Cindy Spence about her book Palliative Touch: Massage for People at the End of Life, how practitioners can protect themselves during this emotional work, and why pressure, pace, and frequency are important aspects when doing hands-on work. Cindy Spence has been a massage therapist specializing in oncology and hospice care since 1999. She believes in the power of choice and pursuit of optimal well-being at all phases of life, particularly during advanced illness and the dying process. Cindy's training includes a master's degree in Public Health and more than 100 hours of continuing education from institutions such as MD Anderson and Sloan-Kettering. Co-creator of Final Touch Training, Cindy is a member of the Society for Oncology Massage, The Hospice and Palliative Nurses Association, and the National Hospice and Palliative Care Organization. As a member of the Oncology Massage Alliance, she provides massage in the chemo infusion room at Baylor Hospital in Dallas. She is also author of Comfort Massage Basics; A Training Program for Nurses and CNA's in the Hospice Care Setting. Cindy finds food for her soul in deep connection with family and friends, quiet time at the beach, long walks with her dog (Pongo), dancing, books, and prayer beads.   Resources:   Palliative Touch: Massage for People at the End of Life: https://us.singingdragon.com/products/palliative-touch-massage-for-people-at-the-end-of-life   Final Touch Facebook: www.facebook.com/finaltouchtraining/       Host: Kristin Coverly, LMT is a massage therapist, educator, and the director of professional education at ABMP. She loves creating continuing education courses, events, and resources to support massage therapists and bodyworkers as they enhance their lives and practices. Contact her at ce@abmp.com.     Sponsors:   Anatomy Trains: www.anatomytrains.com    Healwell: www.healwell.org   Precision Neuromuscular Therapy: www.pnmt.org   AnatomySCAPES: www.anatomyscapes.com       Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.                      Website: anatomytrains.com                        Email: info@anatomytrains.com             Facebook: facebook.com/AnatomyTrains                       Instagram: www.instagram.com/anatomytrainsofficial   YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA       Healwell is creating community and a new kind of massage therapy practitioner all around the world. Check out our courses, join our online community, find us all over the social media universe, and bring your gorgeous self to the conversation!  www.healwell.org Instagram: @healwell_org Twitter: @healwell_org LinkedIn: https://www.linkedin.com/company/healwell/ Facebook: https://www.facebook.com/Healwell.org Check out our podcast, Interdisciplinary, anywhere you get your podcasts!   Therapists who are drawn to Precision Neuromuscular Therapy are problem-solvers who want to learn new approaches, but also understand the “why” behind the “what”.  This desire resonates with our emphasis on the problem-solving process, rather than the teaching of a singular technique or approach. Led by founder Douglas Nelson, each PNMT instructor is a busy clinician with decades of practical experience.   We have taught hundreds of hands-on live seminars for more than twenty years, emphasizing precise palpation and assessment skills. PNMT online courses are another rich source of discovery and deeper understanding. Also available is a video resource library (PNMT Portal) with hundreds of videos of treatment, assessment, pathology, and practice pearls.   Learn more at www.pnmt.org   AnatomySCAPES—created by and for hands-on professionals. As therapists, we want more than labeled charts of muscles, nerves, and bones. We crave anatomy education that informs our touch, and we want the know-how for working with the “stuff” in between. We want the whole story. Led by AnatomySCAPES co-directors, and ABMP Massage & Bodywork magazine columnists, Rachelle Clauson (FRS Fascial Net Plastination Project) and Nicole Trombley (Equilibrio Massage), our in-person lab workshops are in sunny San Diego, not far from the ocean. We teach you what the tissues look like, feel like, how they move, and how they relate to their surroundings. Your eyes and hands learn to “see” what they could not see before. Come join us in the lab in 2023!   Website: www.anatomyscapes.com   FB: facebook.com/AnatomySCAPES   IG: instagram.com/anatomyscapes   YouTube: youtube.com/@anatomyscapes   Email: info@anatomyscapes.com

Dan Behan from Episode 58 is back on the show but in a much more light hearted way. You may know him from Episode 58 where he shares his expereinces in battling cancer. Dan was introduced to the show by Joe Foarile, both men bonded in their battle with cancer at the Sloan Kettering institute and we are fortunate to have him on for antoher round, but with a twist. Dan and Patrick are die hard wrestling fans and its pretty much unavoidable to get them together without discussing some good ole rasslin. However, we do it with purpose here at Men's Health Unscripted, there is actually a lot of men's health or lack there of in the sport of Pro Wrestling. Dan and Patrick are breaking some of these components down in wrestling because its relatable and we believe with a frame of reference this topic can be easily digestable. This is a little off our typical format but we feel its informative and we had a lot of fun preparing and recording. --- Support this podcast: https://anchor.fm/menshealthunscripted/support

How far along is the science of longevity, and are there already proven methods that can increase your lifespan? In this episode, Richard Miller and Joe discuss the massive strides that are happening in the longevity space, and Richard shares the six compounds that have very promising research backing their benefit in improving life expectancy! Richard talks about the problem with certain scientific studies and gives his thoughts on the controversial calorie restriction & longevity debate. They talk about all kinds of drugs, including rapamycin, acarbose, reservatrol, and more, and discuss the one OTC supplement that has positive effects on lifespan! Richard Miler is a Professor of Pathology at the University of Michigan, and Director of the Michigan Glenn Center on Aging. He got his MD and PhD at Yale, did postdoctoral work at Harvard and Sloan-Kettering, and was on the faculty at Boston University until his move to Michigan in 1990. - Find Dr. Richard Miller's work at www.richmillerlab.com - Check out SelfDecode - Join Joe's online community - Follow Joe on Instagram & TikTok

“When you create something,” says ServiceNow CEO Bill McDermott, “that gives you the ability to help and do good and achieve for the most people possible.” Bill left his first corporate job at Xerox for a short stint at Gartner, then served as CEO of SAP for nearly a decade. He made one more transition three years ago because he saw a great opportunity to help make ServiceNow a defining enterprise software company. “I knew it could happen,” he says. “What I didn't know is just how unbelievably right I was.”In this episode, Bill and Joubin discuss fist-pumps, shoplifting teens, Bill's superpowers, needing to be needed, marriage as a partnership, why every relationship matters, difficult relocations, breast cancer, the FDNY's chaplain, and the Medal of Honor. In this episode, we cover: Why Bill bought a deli when he was in high school — and how he competed against 7-Eleven (04:00) Interviewing at Xerox and wanting it more than anyone else (08:17) Unwavering optimism and being a source of strength for others (12:34) How a love of work has shaped Bill as a person (16:44) Facing challenges and keeping a promise to his father (22:00) Enjoying the present and keeping an eye on the future (30:01) Leaving Xerox for Gartner and learning from a tough experience (33:29) Sloan Kettering and Father Michael Judge (39:22) Following the “original dream” vs. building something new at ServiceNow (44:59) Losing an eye and getting a pep talk from two Medal of Honor winners (51:15) Why Bill started and ended his book with quotes from two Kennedys (01:01:21) Links: Connect with Bill Twitter LinkedIn Connect with Joubin Twitter LinkedIn Email: grit@kleinerperkins.com  Learn more about Kleiner Perkins

JCO PO author Dr. Mark Stewart, PhD, Vice President, Science Policy at Friends of Cancer Research, shares analysis on clinical trials and the association between CT-DNA and outcomes in lung cancer. Host Dr. Rafeh Naqash and Dr. Stewart discuss dataset metrics, identification of biomarkers, timepoints, and checkpoint inhibitors, development of new medicines, and novel technologies measuring CT-DNA. Click here to read the article!   TRANSCRIPT Dr. Rafeh Naqash: Welcome to ASCO's JCO Precision Oncology Conversations, where we bring you highlights and overview of precision oncology. Episodes will feature engaging conversations with authors of clinically relevant and highly significant articles published in JCO Precision Oncology. These articles can be accessed at: ascopubs.org/journal/po. Hi, I'm Dr. Rafeh Naqash, Medical Oncologist, and Assistant Professor of Medicine at the OU Stephenson Cancer Center, and you're listening to JCO Precision Oncology Conversations podcast. Today, I am delighted to be talking with Dr. Mark Stewart, Vice President Science Policy at Friends of Cancer Research. We'll be talking about their group's recent paper in JCOPO, titled, 'Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors'. At the time of this recording, my guest and I have no relevant disclosures. Welcome to the podcast, Mark. Dr. Mark Stewart: Thanks. Thanks so much for having me here. Dr. Rafeh Naqash: I am excited to discuss this new publication that your group has come out with, and I see this is a significant effort involving both academia and industry, and also your organization. Could you tell us about what led to this work, and then we can go into finer details about what your findings were? Dr. Mark Stewart: Sure. I might start with just briefly describing our organization. We are a non-profit patient advocacy organization in Washington, DC. And our mission as an organization is really to help accelerate development and access to new medicines. And we do this by doing horizon scanning to see kind of what issues, or emerging technologies, are coming down the pipe that might have implications in oncology. And we bring together experts from universities, government, industry, patient advocacy, to help develop evidence-based policies that can pave the way for future discoveries, but also accelerate the pace of scientific progress. I think that's really embodied in the manuscript that we recently published, and that we'll be talking about today. Dr. Rafeh Naqash: Awesome. And I have come across some of the other phenomenal work that your organization is doing, and this is definitely a step forward in developing more personalized therapies, and trying to identify relevant biomarkers so that we can treat patients and their cancers appropriately. Moving forward, could you tell us some of the main findings from this publication, and then we'll take a deeper dive in trying to understand the kind of data that you used and the kind of analysis that was done? But just as an overview for our listeners, could you briefly explain some of the major findings from this publication? Dr. Mark Stewart: Sure. Maybe in my last answer, I could have provided some rationale in terms of what led us to even initiate this project. So, I think if you look at trends in oncology drug development over the past decade, the use of precision medicines led to really incredible outcomes for patients. I think that's led to really transformative medicines. And with these therapies, if you look at the drug development paradigm, they've often used these expedited development programs at the agency, and that's largely driven by our improved understanding of the biology of the cancer, and the natural history of the disease, and the ability to use endpoints that can read out earlier, that provide us insights into whether a drug is working or not. And as we continue to improve the available treatments that patients have, we're seeing the shift where drugs are starting to be investigated in patients that have earlier disease. And because of that, the length of time it takes to understand whether a drug is working or not can often take much longer because of the follow-up time needed to read out endpoints like progression-free survival, or overall survival. And so, the ability to identify new novel biomarkers that can help us understand whether a drug is working or not sooner would certainly provide a lot of value to drug development, it could help expedite the development of new, innovative therapies for cancer patients. And I think like everyone else, when we first saw a lot of the emerging data coming out on the role of circulating tumor DNA and its potential role in clinical research and care, I think there was a lot of excitement around the potential. And when you look at all these exploratory studies, you see a lot of potential for using ctDNA changes to signal whether a drug is working. But a lot of these initial studies were conducted independently, using different methods, different technologies for measuring ctDNA, and this really left questions about the applicability of this from a more rigorous standpoint, and how this might be applied in a regulatory setting. And so, we brought together a diverse group of scientific leaders to really design a comprehensive plan that could leverage these prior studies, and then bring them together in an effective manner to where we can increase our power, strengthen our understanding of this association that we see between changes in ctDNA and outcomes. And so, this manuscript is really a first iteration of several data readouts we have planned over the next year. This first study included five different clinical trials of patients with lung cancer that were treated with immune checkpoint inhibitors. And I think one of the figures that I think is most interesting to see in this, is actually our FIG 1., where it's a swimmer plot, where it really shows the differences across all these different trials, and it also exemplifies some of the challenges that we had to overcome when we brought all these datasets together, but yet still arrive at some meaningful data to address our core question of whether changes in ctDNA can predict treatment outcomes. Dr. Rafeh Naqash: So, definitely an exciting endeavor that you guys have brought forward this aspect of ctDNA. So, in my other life I'm involved in a lot of early-phase clinical trials, and my patients often ask me, "How is it that you're going to assess our response? How long will we be on treatment?" And currently, as most of our listeners know, the standards are primarily using CT scans, or other imaging modalities to assess for responses, and with the innovation that's being made in the field of circulating tumor DNA, it's definitely transforming the world and innovations on the precision oncology side. For example, in GI cancers, there's been significant development, there are clinical trials in this setting. In the lung cancer setting, there are clinical trials trying to assess ctDNA-related changes, and treatment changes associated with those alterations, or decrease, or increase, in the ctDNA. So, based on what you describe here from the understanding that I have reading through this interesting paper, you used, as you mentioned, previously-conducted clinical trials. Could you tell us a little more about what kind of clinical trials were these, and for non-small cell lung cancer, and what kind of therapies patients were treated with in these clinical trials, and how did you determine which clinical trials you would use for this project? Dr. Mark Stewart: Sure. When we first launched this project, we basically put a call out to various drug developers, academic investigators, to see what types of data were even available. And at that time, maybe not a surprise to many, there was a lot of ongoing clinical trials that were measuring ctDNA in patients with lung cancer. And because of that, we found a number of clinical trials that kind of fit a general criteria that we felt could be brought together as part of this initial analysis. We tried to keep the criteria broad, we didn't want to be overly exclusive. So, we didn't limit the studies to having to have used a specific assay, for instance, and we thought that that was an important component here because we wanted to understand whether this phenomenon of changes in ctDNA being associated with outcomes isn't necessarily due to a specific technology. And I think the strength of this becoming a potential endpoint is that it is something that can be reproducible and repeated regardless of the kind of technology that was used. The clinical trials, it's also important that they had multiple timepoint collections while the patient was on treatment because there's still questions remaining around what's the right time to collect ctDNA, and which timepoints are most correlative to long term outcomes. And we thought those were important things to begin to investigate in our study. And so, it was really the availability of data that naturally led us to first starting in lung cancer. Dr. Rafeh Naqash: Sure. Thank you for that explanation, Mark. And to the best of my understanding, when I read through some of the details in the manuscript, there's a mention that these were five clinical trials. Patients had been treated with either immunotherapy alone, or immunotherapy with chemotherapy, both being the standards of care, depending on some of the other biomarkers and disease burden. But from a ctDNA perspective, it seems that you were trying to include mostly patients that had at least two assessments done at baseline, no earlier than 14 days, and at least one within the first 70 days of treatment initiation. Is that a fair understanding from what has been described in the manuscript? Dr. Mark Stewart: Yes. And we didn't limit as well to a specific immune checkpoint inhibitor. Again, for us, our goal was to cast a broad net and try and include as many clinical trials as we could in this first analysis. Dr. Rafeh Naqash: Right. And I guess, based on the data that you have used in this project, there's obviously heterogeneity with the trials, with the treatment, with probably different lines of therapies that the patients had been treated with, so, that is probably why you were trying to explore different metrics of this ctDNA change. And there's a couple of metrics, it seems, that you and your team have assessed here; one of the metrics that seemed to stand out was this metric where you used three different categories of patients that, depending on the change in the ctDNA, whether they had a decrease, an intermediate category, and a category that had an increase. So, Mark, based on the findings on the paper, it seems that you're using different ctDNA-based metrics to assess changes in responses and survival. Based on the methodology, what was the most appropriate, or the strongest one that you were able to identify that was associated with differences in survival, and responses as you've sort of explained in the manuscript? Could you describe that briefly for us? Dr. Mark Stewart: When initiating the study, there were a lot of unknowns in terms of how we would be able to bring together these different datasets, particularly knowing that they use different ctDNA assays that potentially included targeted panels, and whole genome sequencing, and also had different kind of readouts and metrics that were used. And so, early on we explored various metrics. And the one that rose to the top was a variant allele frequency, which is simply the number of mutant alleles divided by the total number of mutant and wall-type alleles. And there's different ways you can report that out -- it could be a mean, it could be a median, or a maximum. While we didn't necessarily see large differences between those, we did observe that consistently, maximum VAF correlated with overall survival and was one that we continued to use as a primary analysis in our manuscript. Dr. Rafeh Naqash: So, Mark, based on some of the analysis you've done here, was a landmark timepoint used to compare survival for the patients because there could be a difference in the number of timepoints of ctDNA assessment for different patients, which would, in turn, mean that some patients could have been treated longer versus some other patients? So, did you try to limit that heterogeneity by performing a landmark analysis on this cohort? Dr. Mark Stewart: Yes. That was one of the approaches we had to take, given the heterogeneity across the different studies that we included in this analysis. In FIG 2., again, you can see across the five different studies how there are different numbers of ctDNA timepoint collections, but also that they were collected at different timepoints. And so, to try and create a more equal playing field and informative analysis here, we did use a landmark of 70 days here and used ctDNA timepoints that were around that landmark when we were looking at the association between changes at that particular time to overall survival, or progression-free survival. Dr. Rafeh Naqash: So, Mark, based on what you've shown here as far as overall survival is concerned, could you tell us about how the specific ctDNA metric that you used was able to compartmentalize patient survival on checkpoint inhibitors? Dr. Mark Stewart: Sure. As I'd mentioned previously, in this analysis, we used a three-level variable to differentiate response to treatment using ctDNA. This three-level ctDNA metric represented patients that had a decrease in ctDNA from baseline, an intermediate change, or an increase. And so, for each of these three ctDNA metrics, we were able to bucket patients into these three categories based on the percent change and varying allele frequency. And so, those that had the 50% decrease in ctDNA were bucketed in the 'decrease' category, and those that had a 50% change in the positive direction were bucketed in the 'increase', and then all the patients that remained were placed into the 'intermediate' category. And as you can see from the Kaplan-Meier Curves, I think a quite robust differentiation between those three groups. Dr. Rafeh Naqash: Right. And another interesting finding on one of the forest plots that you've shown is that patients who smoked had a better survival or better outcome with therapies. And I remember a couple of years back reading an interesting paper in Science, if I remember correctly, from a group at Sloan Kettering, showing the increased neoantigens and mutational burden related to smoking, that probably predicts better responses. Is there any other interesting aspect to this from a ctDNA standpoint that your group was able to identify, or is looking at, at least in this comparison of smokers versus never-smokers? Dr. Mark Stewart: Yeah. Actually, when we took into account all the different clinical variables that were included in these datasets, we actually saw an association between patients that were smokers or had smoked at one point, and the ctDNA levels that were present. Despite that smoking may impact the levels of ctDNA present, I think, the fact though, that we are trying to determine whether a treatment is working, or not, based on a change, or a delta, between a baseline and a subsequent timepoint, it shouldn't really matter necessarily what your baseline is, so long as you're still able to observe a decrease or an increase. Dr. Rafeh Naqash: From, I guess a futuristic perspective since this project primarily involved pooling of data from five different clinical trials, is there a plan to validate some of this in an independent cohort of patients in the next year to two years? Dr. Mark Stewart: Yes. As I mentioned, the CT Monitor project that we've developed into multiple different modules, and the modules have been broken up basically in terms of when data is available in different clinical trials. And so, we've continued to work with different drug sponsors and academic investigators to put together data use agreements, and I'm excited to say that we have three different modules that we plan to read out over the course of this next year. We have a module that includes patients with lung cancer that are treated with a TKI - Tyrosine Kinase Inhibitor. We have a second module that is an additional analysis in patients with lung cancer treated with immune checkpoint inhibitors. I think a key thing to highlight there is that the studies that we'll include in this next round are all randomized clinical trials, and so, we'll be able to look at the ability to differentiate between two treatments using ctDNA, and understanding its kind of predictive nature as a potential endpoint. And then the third module is really kind of a catch-all that includes multiple different cancer types, and where patients have been treated with either a Tyrosine Kinase Inhibitor or an immune checkpoint inhibitor. And across all of those studies, we have about 22 different clinical trials that'll be included in those analyses that represent over 3000 patients. And so, I do think we'll be able to validate the findings that we've been able to show in this latest publication, and also address some additional questions. Many of these studies are newer, so I think people have learned from some of the earlier clinical trials that included ctDNA. So, in these latest studies you see many more collection timepoints. You also see earlier collection timepoints even before the first RECIST measurement. So, I think we'll be able to understand, again, get greater granularity on, what are the optimal timepoints for collecting ctDNA; how early can ctDNA predict clinical outcomes; and finally, just to add to that body of evidence that can hopefully help provide confidence to the community that this is an objective and meaningful measure, and that could hopefully be used in a regulatory standpoint as a potential early endpoint that could serve as a basis for a drug approval. Dr. Rafeh Naqash: Those are all awesome, phenomenal things that need to be accomplished, definitely, and your organization is leading these efforts in a one-of-a-kind public-private partnership. And I completely agree with you that this could be a very important biomarker metric for patients who are treated with novel therapies, including checkpoint therapies, Tyrosine Kinase Inhibitors, or even potentially, on clinical trials. From a practical application standpoint, Mark, has your organization also made any efforts in terms of trying to see how we can try to get both FDA and insurance approval for patients who are treated on standard of care therapies but would benefit from having serial, you know, every four to six months ctDNAs done? Because I try to do that sometimes in my practice and do face occasional challenges from insurance companies where they're not willing to pay for repeated ctDNA assessment. And I try to space it out when I'm not getting CT scans, you know, alternate it with CT scans. But is there any kind of an effort in that direction where from a regulatory standpoint, in the next one to two years, we can make progress so that clinicians are able to order ctDNA on patients, whether they're treated on checkpoint therapies or other targeted therapies? Dr. Mark Stewart: That's a critical issue that you raise, and certainly a potential barrier that can prevent patients from benefiting from this novel technology. To date, our efforts have been mostly focused in kind of the use of ctDNA in the research space, but I think that they're not mutually exclusive. I think one important way to ultimately get coverage for these tests is to have that evidence base that really shows the utility that it is providing benefit to patients. I look at this as kind of a first step to getting there, and I think once you have this evidence, and also you have the right evidence that we know payers want to see, that hopefully, it can help address those potential concerns. Dr. Rafeh Naqash: I could not agree with you more. And your work, definitely, is a step forward in the right direction, and I think will lead to a lot of exciting subsequent things, as you mentioned. I congratulate you and your group again, on this exciting project, and I appreciate that you chose JCO Precision Oncology as the final destination for this phenomenal work. Dr. Mark Stewart: Thank you for having me. And certainly I just want to extend gratitude to my fellow authors. I think we have around 34 authors on this manuscript, and I think it just, demonstrates the recognition that this truly does require collaboration across different stakeholders, and look forward to next steps. Dr. Rafeh Naqash: Thank you so much, Mark. Thank you for listening to JCO Precision Oncology Conversations. You can find all our shows, including this one, at: asco.org/podcasts, or wherever you get your podcasts. To stay up-to-date, be sure to follow and share JCOPO content on Twitter with the handle: @JCOPO_ASCO. All JCOPO articles and series can be found at: ascopubs.org/journal/po.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.   Guest Bio Mark D. Stewart, PhD, is Vice President, Science Policy at Friends of Cancer Research in Washington, DC, an advocacy organization that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients.  

Today we had a fascinating discussion with Dr. Michael Werner of MAZE Men's Sexual Health, a board-certified urologist who received specialized fellowship training in male infertility and surgery and male sexual dysfunction at Boston University Medical Center. Dr. Werner lectures and writes extensively on these topics in medical journals and books, and his practice is limited to male infertility and sexual dysfunction. More importantly, his concentration in these areas means he practices the latest and most advanced treatments and surgical techniques, ensuring his patients' greatest likelihood of success. Dr. Werner shares why he wanted to go into male infertility and his exciting work, including banking trans women's sperm before hormonal treatment at Sloan Kettering. He discusses his unique expertise in Extended Sperm Search Microfreeze (which helps almost 100% of men with minimal sperm retrieve sperm), sperm mapping, and vaginismus. We also had the incredible opportunity of asking Dr. Werner YOUR questions including which lubricants affect sperm, what a visit to MAZE might look like, sexual dysfunction in the Jewish community, and talking about masturbation with our children. Dr. Werner, thank you for your time and for sharing your incredible expertise with us! We learned so much and we know our audience will as well. For more information about Dr. Werner, visit @mazemenshealth on Instagram.

In today's episode, we finish up our conversation with Rose Marie as she talks about how to deal with difficult clients and with that the importance of setting boundaries.  Check it out :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

In this episode, Rose Marie dives into her most memorable client experience. You don't want to miss this! Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

In this episode, Rose Marie shares the best piece of advice she's ever been given. Specifically, she talks about the importance of preventing burn-out in your life! Check it out! Are you someone interested in becoming a PMU artist but are scared to take that first step? In this episode, we continue our conversation with Rose Marie as she shares her advice for those looking to take that first step in the beauty world. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Have you ever wondered how a PMU artist earns the trust of their first-ever client? Even without any before-and-after photos or history with the client? In this episode, Rose Marie talks about the importance of authenticity and letting your passion shine through when interacting with clients for the first time. You don't want to miss this! Are you someone interested in becoming a PMU artist but are scared to take that first step? In this episode, we continue our conversation with Rose Marie as she shares her advice for those looking to take that first step in the beauty world. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Our conversation with Rose Marie continues as she gives advice for up and coming artists who may be feeling nervous or not confident when starting their PMU career. Tune in! Are you someone interested in becoming a PMU artist but are scared to take that first step? In this episode, we continue our conversation with Rose Marie as she shares her advice for those looking to take that first step in the beauty world. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Our conversation with Rose Marie continues as she delves into other skills outside of artistry that she believes all PMU artists should learn. Check it out! Are you someone interested in becoming a PMU artist but are scared to take that first step? In this episode, we continue our conversation with Rose Marie as she shares her advice for those looking to take that first step in the beauty world. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Are you someone interested in becoming a PMU artist but are scared to take that first step? In this episode, we continue our conversation with Rose Marie as she shares her advice for those looking to take that first step in the beauty world. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Surviving Stage 3C and Stage 4 colon cancer and their treatments and overcoming their long-term side effects taught Jay Einbender that cancer is not just a journey of the body, but equally a journey of the mind and soul. And that all three must be treated concurrently. 01:56: I started having symptoms in my lower left abdomen. 04:27: Why was it such a nightmare? 06:06: I had my chemotherapy at Sloan Kettering. 08:35: It cost $10,000 a shot to keep my white blood cell levels high. 10:35: I slept on average three hours a night. 12:48: Cancer stresses your finances from the very beginning.  14:43: What did you do before cancer? 17:57: She's the number one lung transplant doctor in the United States. 20:59: What was the worst moment for you? 23:04: People always think of me as an extrovert, but I'm really an introverted extrovert. 24:19: How about your best moment?  27:10: What is one thing you wish you had known at the beginning? 31:18: if you could only do one thing to improve health care in the U.S., what would it be and why? 32:41: Thriver Rapid Fire Questions.  34:08: Aside from Cancer U, what's one resource you would recommend for cancer patients and caregivers?  Resources HeartfirstHeartfirst on FacebookEmail Jay  

In today's episode, Rose Marie shares what her favorite thing about being a PMU artist is and how life-changing it can be. You don't want to miss this! Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

In today's episode, Rose Marie shares her favorite type of beauty service out of all the services she offers to her clients. Check it out! Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

In today's episode, we continue our conversation with Rose Marie as she shares her process of gaining all the beauty certifications in her career and what it means to be hungry for knowledge. Tune in :) Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

In today's episode, Rose Marie of the Beau Institute of Permanent and Corrective Cosmetics shares with us her journey in becoming an PMU artist and what it was like receiving her first beauty certification. You don't want to miss this! Meet Rose Marie: “I never tire of watching the transformations and the exhilaration they bring about. I feel so blessed to have found this profession, and it gives me great pleasure to share my knowledge with all who are interested in learning.”  Beau Institute founder Rose Marie Beauchemin-Verzella is an internationally acclaimed expert in the field of permanent cosmetics, microblading, areola tattooing, permanent camouflage, and color lifting, with more than 29 years of experience as an industry leading practitioner, trainer, and speaker. Her talents  and business acumen have allowed it to grow into one of the top permanent makeup institutes in the world.   As an Instructor…Rose Marie displays her passion for excellence in her extraordinary teaching abilities that pave the way for her trainees to become excellent practitioners. Her patience and thoroughness allow her to educate trainees in the physical skills while instilling the confidence they need to launch their own successful permanent makeup careers. Rose Marie's students hail from around the world including the United States, Australia, India, Azerbaijan, Van Couver, Oman, South Africa, Amsterdam, Egypt, Bermuda, United Kingdom, Switzerland, and Latvia. They include medical professionals from prestigious medical institutions from Sloan Kettering,  University of Pennsylvania, Columbia University's Stephanie Spielman Breast Cancer Hospital, City of Hope, Long Island Plastic Surgery, Garden State Plastic Surgery, and many more. Training classes consist of surgeons, physician's assistants, nurses, aestheticians, as well as makeup artists, tattoo artists, and newcomers to the field. Many of the certified trainers in the United States have trained under Rose Marie's instruction. Rose Marie's dedication to helping breast cancer patients restore their physical and emotional health, as well as their self-confidence, is made clear by her founding, The Beau Institute's Annual Day of Hope, where areola tattooing is performed, complimentary. This year, with the help of the AAM, The Beau Institute's x Day of Hope has swept across 7-countries. Countless women were helped to regain their femininity and familiarity.  Rose Marie is a contributing author of the medical text called Micropigmentation Millennium, with Dr. Charles Zwerling, Ophthalmic Surgeon, and Dr. Norman Goldstein, former Chief of Dermatology, University of Hawaii, and Dr. Linda Dixon. She was also referenced as an expert in another medical text, Micropigmentation: State of the Art also by Dr. Norman Goldstein and Dr. Charles Zwerling.  Rose Marie is a supporter of the TLC Foundation for Body-Focused Repetitive Behaviors (BFRBs), which provides valuable information and assistance to those struggling with Trichotillomania. She has performed countless permanent eyebrow procedures on clients who struggle with Trichotillomania, as well as Alopecia. She is a member of the Phoenix Burn Society and teaches camouflage for Self-Injury scars and Vitiligo. Find Rose Marie on Insta: @beauinstitute

Pride Month may be over but MFQC Pride Summer is still underway! Welcome back for Week 2, y'all! This week on the show we welcomed MFQC newcomer Cassie Chartier (she/they) as our guest host! Cassie chatted with Viktor Belay (he/him), a PhD student at Weill Cornell Medicine and Sloan Kettering Cancer Center. They discussed science communication in the time of COVID, Viktor's journey to Tiktok, how scicomm and scipol intertwine, and much more! This episode is benefitting the Ali Forney Center (chosen by our guest host, Cassie) and the GoFundMe fundraiser is LIVE (https://gofund.me/fa594ef4) and will close 7/14. To connect with Cassie and Viktor you can follow them on Twitter @cassie_chartier and @BelayViktor (and us @MFQCPod). We'll see y'all next time and remember that Black Lives Matter today and everyday.

In part one, of this two-part ASCO Education podcast episode, host Dr. Jeremy Cetnar (Oregon Health & Science University) interviews two very accomplished physicians and researchers, Dr. Lauren Abrey and Dr. Jason Faris. We'll hear about their motivations for pursuing medicine and how they arrived at the different positions they've held in academia and industry.  If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org.   TRANSCRIPT   Dr. Jeremy Cetnar: Hello, and welcome to the ASCO Education podcast episode on career paths and oncology. My name is Jeremy Cetnar. I'm a Medical Oncologist and Associate Professor of Medicine at Oregon Health and Science University in Portland. I'm delighted to introduce today's two guests, whose careers in oncology have crisscrossed academia and industry. Dr. Lauren Abrey and Dr. Jason Faris, I'm excited to chat with you about the inspiration and motivations that drive you, people you've leaned on, how you've made your career decisions, challenges you've faced, and more.  So let's start by asking each of you, could you share a little bit about your early life and background, what attracted you to medicine, and who are some of your early mentors and role models? Let's start with you, Dr. Faris.  Dr. Jason Faris: Yeah, I'd be happy to. Thank you. So, I grew up in a small town in South Jersey in Greater Philadelphia. My mom was a registered nurse in pediatrics in the maternal infant unit for many years at Cooper Hospital. I was always interested in science and medicine and my mom's dedication to her patients. Her altruism and compassion served as a real inspiration for me, for my eventual decision to go to medical school. But I took a long time to get there. I had a bit of a circuitous route to arrive to my career in medicine though it started off conventionally enough. I was initially geared towards a premedical track in college, majoring in biology, but an exciting summer research project, working on the biochemical mechanisms underlying osmoregulation in a marine crustacean with mentoring from my first true mentor, Dr. Don Lovett, led me to apply to and attend graduate school in molecular biology at Princeton.  This was followed by a position at Merck as a molecular biologist in the genetic and cellular toxicology group. I went to veterinary school at the University of Pennsylvania where I met my future wife. And then finally, back to the original plan of attending medical school, but I have to say with a much better sense of why I wanted to attend medical school in the first place, now in my late 20s, which was a bit unconventional at the time. I really did my fair share of exploration of Allied Health careers. That's for sure. I attended Johns Hopkins for medical school, where I quickly discovered a passion for internal medicine. And that was far and away my favorite clerkship and sub-internship. That's the background to how I got to medical school.  Dr. Jeremy Cetnar: Dr. Abrey?  Dr. Lauren Abrey: Interesting. I love your story. We share... I grew up in a small town, not so far away, but I was in upstate New York. And I think there were two influences that kind of got me to my ultimate passion for brain tumors. And this sounds a little quirky to start with. But I had a pretty serious head injury as a tween. So I guess I was about 12. I had a skull fracture, epidural hematoma. And while I would never have said I woke up at that moment and thought I have to be a doctor, I think I became fascinated about things to do with the brain.  In parallel, something that I think tinged a lot of my childhood was a number of family members who had cancer. So both of my grandmothers had breast cancer, while I was well aware of the fact that they were sick and battling this. And two of my aunts also had cancer. And I would say it's an interesting split in my family. So about half of them are survivors and about half ultimately died of their disease.  So both of these things really motivated me or focused me on the need to do something important, but also to do something that really motivated me to get out of bed in the morning. I think I was much more to the point. I went straight to college, straight to medical school. I remember calling my parents and telling them I was applying to medical school and having them say, “Wait. You? Really?” So it wasn't necessarily the family expectation that I would do this, but I was very driven and motivated to make some of these choices and then discover my particular interests as I progressed through medical school. So I went to Georgetown for medical school and then have trained at a number of places in the US. I think that's a little bit how I took my first step on this career journey, let's say.  Dr. Jeremy Cetnar: So take us through what the decisions were like in your head at the end of fellowship in terms of first jobs. Dr. Faris?  Dr. Jason Faris: In terms of my choice to pursue a career in medical oncology, this goes back to medical school during an internal medicine clerkship. I had an assistant chief of service, ACS, at the time, Phil Nivatpumin. He'd go on to become a medical oncologist. He really inspired me with his optimism and bedside manner, including with multiple oncology patients on that clerkship. His enthusiasm for science and medicine, his teaching skills, and an absolutely legendary fund of knowledge. For Phil, he was just an incredible ambassador for both internal medicine and for oncology.  After medical school, I went to internship and residency at Mass General Hospital. And in one of my first rotations, I was on the oncology service, which was not so creatively called Team Three. I think they can up the ante there, but oncology services on Team Three. I was caring for many extremely ill patients battling disease progression from their metastatic cancers, or sadly, in many cases complications of their treatments. During that rotation, I was intrigued by clinical trials offering novel treatment options based on cutting edge science, but also struck by the number of patients who just didn't have any clinical trial options. I became aware of the limitations of the conventional treatments that were offered.  I was really inspired by the patience and dedication of the nurses and doctors caring for them. And I vividly recall a roughly 50-year-old woman I helped care for with AML, watching as the 7+3 chemotherapy caused lots of side effects for her and being amazed by her strength and grace, her resilience as she faced her illness, her potential mortality, and the intense chemotherapy she was undergoing. And I knew during those moments with that leukemia patient while caring for other patients on that oncology service that this was the field I would pursue. Oncology was really the perfect blend of humanism, problem solving, longitudinal follow-up and rapidly accelerating scientific progress leading to new avenues for clinical trial treatments.  Like Lauren, I was motivated and inspired by cancer diagnoses in my own family. My maternal grandmother died of pancreatic cancer during my junior year of college. My dad was diagnosed with colon cancer during my first year of fellowship. So those are all really strong motivators, I would say. And after completing my fellowship at the combined Dana-Farber MGH program, my first position out of fellowship was in the gastrointestinal cancer group at MGH. I actually had been training in genitourinary oncology after my main clinically focused year of fellowship, but I did a chief resident year in the middle of fellowship, and that was the tradition at MGH. And as I was about to return to fellowship for my senior year of fellowship, the head of the GI Group and head of the Cancer Center at the time, Dave Ryan, offered to serve as a clinical research mentor for me in GI cancers. As a senior fellow, I wrote an investigator-initiated trial of cabozantinib for patients with neuroendocrine tumors under his mentorship that went on to demonstrate encouraging results, led to a Phase III study in that cancer population, and I ultimately accepted a position at the MGH Cancer Center in the GI cancer group about 11 years ago. And that was the start of my post-training career.  Dr. Jeremy Cetnar: And how about you, Dr. Abrey?  Dr. Lauren Abrey: So for people who don't know, I'm actually a neurologist. I finished my training in neurology and then pursued a fellowship in neuro oncology. I would say it was really patients and observations of things that were happening with patients during my residency. I did my residency at the University of Southern California at Los Angeles. I was at the LA County Hospital, which for people who don't know, is one of the largest hospitals in the country. I had the chance to see several patients who had paraneoplastic syndromes, and got the support from different faculty members to write those cases up, and really resulting in my first independent publications. That was what kind of got me bitten by the bug to understand this link between neurology and oncology.  I very intentionally went to Memorial Sloan Kettering to have the opportunity to work with Jerry Posner. And I think I no sooner got there than I got totally bitten by the brain tumor bug, which seems a little counterintuitive. But the paraneoplastic work was kind of deep laboratory work. And I realized that I really enjoyed seeing the patients having the partnership with neurosurgeons and digging into what is still a pretty intense unmet medical need.  So it was an interesting pivot because I really thought I was going to Sloane to focus on paraneoplasia. I still think I learned so much with that interest that I think we can reflect on when we consider how immunology has finally entered into the treatment landscape today for different tumor types and understanding is there a background in paraneoplastic disorders that could help us. But I have to say it was really the brain tumor work that got me focused and the chance to work with people like Lisa DeAngelis, Phil Gutin, and others that was kind of fundamental to my choices. I stayed there for two years of fellowship and then continued as faculty for about another 15 years at Sloan Kettering. So that's really the start of my academic career and the pivot to industry came much later.  Dr. Jeremy Cetnar: So both of you have impressive career CVs, have been trained at very prestigious institutions. So at some point in time, take me through, what was that transition like between, 'Hmm, what I'm doing is enjoyable, but maybe there's something else out there that I want to explore.' And what I mean by that is mostly industry at this point. So that's an important question that I think a lot of junior faculty face, a lot of mid-career faculty, maybe even later-stage faculty. But I think that's a tension point for a lot of people because I think there's a lot of fear. I think there's a lot of anxiety about moving outside of the academic realm. So, tell us a little bit about what was the pull in terms of going to industry and what were some of the thought processes that were going on. Dr. Faris?    Dr. Jason Faris: I've experienced two transitions, actually, between academia and industry. I like to do things in pairs, I guess. But the first was, after multiple years at the MGH as a resident fellow and as a clinical investigator at the MGH Cancer Center. As a new attending and clinical investigator, I was attempting to balance my work priorities, providing patients with GI cancers, which is a rewarding but complex and I'd say emotionally intense experience, given the phenomenally aggressive and devastating cancers these patients grapple with such as pancreatic cancer, alongside the other responsibilities of my clinical investigator position.  Those other responsibilities included writing grants and papers and protocols, evaluating patients who were interested in open clinical trials, and serving as the principal investigator for multiple studies. I was serving on committees, mentoring and teaching. Patient care was always my top priority as it should and really must be. And I feel incredibly lucky to have had truly amazing colleagues at MGH across several disciplines, from medical oncology, nurse practitioners, practice nurses, radiation oncologists, and surgeons. It was and continues to be a dynamic place full of extremely talented and dedicated clinicians. I think we really all benefited from the coordinated teamwork in both patient care and research in a really tight-knit GI Group.  But nonetheless, for me as someone who delighted in spending large amounts of time with my patients in the clinic rooms, and I think my colleagues would agree frequently agonizing over decisions impacting their care, achieving sufficient balance to really focus on writing and overseeing clinical trials was becoming increasingly challenging for me. And it was in that context, after spending roughly a decade and the combination of residency fellowship training and as an attending in the GI cancer group all at MGH that I made a truly difficult decision to move from my beloved outpatient clinical and clinical investigator role to industry to focus more exclusively on clinical research.  And after interviewing for several industry-based roles, I accepted a position in the early-phase group at the Novartis Institutes for Biomedical Research or NIBR as we kind of pronounced those words in Cambridge. I absolutely loved my time at NIBR. It's an incredible place with a strong history of and commitment to innovation as well as passionate, talented colleagues, many of whom I've worked with in the past. When I first started at Novartis, I was amazed at the array of experts on the teams I was helping to lead as a clinical program leader. Our teams are the definition of multidisciplinary. They're composed of what we call line function experts in multiple disciplines. This includes preclinical safety experts who design and analyze data from studies that precede the filing of an IND, research scientists, chemists, preclinical, and clinical pharmacologists, statisticians, program managers, drug and regulatory affair colleagues, who focus on the interactions with health authorities, including the FDA, operational colleagues called clinical trial leaders, and many others.  In my role as a senior clinical program leader, I also have the opportunity to collaborate frequently with research colleagues on preclinical programs, designing and writing first in human trials, followed by conducting the actual studies and in close collaboration with our academic colleagues, analyzing the clinical and translational results.  Dr. Jeremy Cetnar: Dr. Abrey, how about you? Was there a moment or what were the moments that led to you deciding to make this transition?  Dr. Lauren Abrey: I guess I have the other sort of story. I got pushed, I would say, in the sense that like many of us, I'm married, and my husband was the one who took a job with Novartis and said, “This would be an adventure. Let's go live in Switzerland.” So similar to Jason, he took a position at NIBR, and I think for many of the same reasons, he really wanted to delve deeply into early mechanism of action and allow himself to dedicate really a chunk of his career to developing key drugs. But moving to Switzerland changes your options suddenly. I think I had spent most of my career at Sloan Kettering doing clinical trials. That was really my comfort zone, my sweet spot. And when we moved over here, I explored briefly, could I set up an academic career here?  And very kindly, I was invited by a number of Swiss colleagues to look for opportunities to do that. But I realized what I loved was talking to patients, and that that was going to be difficult with the language barrier. And I equally loved running clinical trials. So I had a great opportunity to join Roche shortly after their merge or full acquisition of Genentech. This allowed me to continue the work I had been doing on Avastin for brain tumors.  But I think the other thing that allowed me to do, that was something I was really looking for was to broaden my scope and to no longer be niched as just a brain tumor expert. And if you're in academia and you're a neurologist, obviously, you're going to be fairly constrained in that space. But moving into a role in industry really allows you to look much more broadly and work across multiple tumor types. And I spent the next seven years at Roche running not just the Avastin teams that were developing drugs for a number of indications, but really overseeing the clinical development group based in the European sites. And they had about 14 different drugs in different stages of development as well as partnerships with their early research group that was European based.  So it was a fascinating time for me, and I feel kind of like I got thrown into the pond. I knew a lot about clinical trials. I had no idea about so many other aspects of what I needed to consider. And I think Jason started to allude to some of this with the different line function expertise and things I think we take for granted or maybe we simply have blind spots around them when we are sitting in our academic organizations. So it's been a really delightful plunge into the pool. I've continued to swim mostly. Occasionally, a little bit of drowning, but a lot of fun.  Dr. Jeremy Cetnar: What would you say are the major differences between an academic career and industry?  Dr. Lauren Abrey: I think, as you said, the things that are similar is that the purpose or the mission for both is in many ways the same. We would like to develop better treatments for patients with cancer. And so there's a huge focus on clinical trials. There needs to be a huge focus on patients, and that can get diluted in industry. I think the things that you don't appreciate sometimes when you're sitting on the academic side is just really the overarching business structure and the complexity of some of the very large organizations. So you suddenly are in this huge space with people focused on regulatory approvals focused on pricing, focused on manufacturing, focused on the clinical trial execution, and why you are doing it in different spots.  And so I think some of the different factors that you have to consider are things that again, we either take for granted or are super focused when you're in one organization. And I think the tradeoffs and how decisions are made, particularly in large pharma, can be frustrating. I think we are all used to applying for grants or getting the funding we need to do whatever our project or trial is. And then you just start very laser focused on getting to the end. If you're in a large organization and they have a portfolio where they're developing 14, 15, 20 different things, you might suddenly find that the project you think is most important gets de-prioritized against something that the company thinks is more critical to move forward. And that could be because there's better data, but it could also be because there's increasing competition in the space or there's a different pull for a large company. I haven't seen the early development side as much. I've seen the development. I've now seen Medical Affairs for how some of those decisions are made, but I'd be curious to hear what Jason has seen in some of his experiences as well.  Dr. Jason Faris: Comparing and contrasting a little bit between the two, because I've run early phase studies on the academic side, I'll talk more about that in a little bit in terms of another academic position that I held. So I've run early-phase studies there. I've run early-phase studies in industry as well. And they share a lot of similarities, certainly following compelling science, the excitement about new therapies that are going to be offered to patients. But I think the execution is a bit different, and I would say, when you're running clinical trials in the academic setting, you're meeting every patient that you're going to put on study or at least one of your colleagues is, if you have sub-eyes on the study, that's a major, major difference, right? You're directly taking care of a patient going on to an experimental therapy, consenting that patient, following them over time, getting the firsthand experience and data from that patient interaction, but not necessarily, unless you're running an investigator-initiated study, not necessarily having access to the data across the whole study.  You're hearing about the data across the whole study at certain time points on investigator calls, PI meetings, dose escalation meetings, those kinds of things. But you're not necessarily having access to the real-time emergence of data across the whole study from other people's patients. So you're a bit dependent on the sponsor to provide those glimpses of the data, synthesize that and present overview. So those are some operational differences, I would say, because you're not taking direct care of the patients and having your time split among different commitments in that way I have felt a greater ability to focus on the clinical research that I'm doing in my industry-based role, which I like, of course, but I also miss taking care of patients. I love taking care of patients.   So I think it's always a double-edged sword with that if we can use a sword analogy here. But I think they both offer really exciting options to pursue new therapies for patients, which for me, was one of the fundamental reasons that I pursued medical oncology in the first place. It was really this idea that the field is rapidly advancing. I wanted to be a part of that. I saw firsthand what cancer could do to my family or family members, and I took care of patients in the hospital as an intern resident and fellow where I think there's just a tremendous unmet medical need. And so having an opportunity to contribute to the development of new therapies was always a real inspiration for me.  Dr. Jeremy Cetnar: With that being said, what led you to go back into academia?  Dr. Jason Faris: This is an ongoing saga, I guess. So after several years of professional growth at Novartis, gaining experience with designing and conducting clinical trials on the industry side, I was actually at ASCO and I learned of an open role for the director of the early phase trials program at Dartmouth's Cancer Center. After extensive consideration, which I think you can see as my trademark at this point, I made another difficult decision to interview for the position, which was focused on helping to grow the early phase trials program at an NCI comprehensive designated cancer center that's unique in a way because it's in a rural area. And it had a new director of the Cancer Center, Steve Leach, who's a renowned laboratory scientist with a focus on pancreatic cancer and a surgeon by training.  I ultimately decided to accept the early phase director position, moving my family away from Greater Boston, where we had lived for about 15 years, to the upper valley of New Hampshire. And while at Dartmouth, I was part of exciting projects, including writing and overseeing an NCI grant called Catch Up, which was geared towards improving access to early phase clinical trials for rural patients. I opened numerous sponsor-initiated immunotherapy and targeted therapy, early phase trials. Just to say a little bit about Dartmouth's Cancer Center - I think they also benefit from tremendous collaboration, this time across Dartmouth College, the Geisel School of Medicine, the School of Public Health. I think they provide really excellent care to their cancer patients. And I was extremely proud to be part of that culture in the GI Group, which was much smaller than the one at MGH, but also an incredibly dedicated group of multidisciplinary colleagues who work tirelessly to care for their patients.  But nonetheless, less than six months into that new position, the COVID pandemic started, and that introduced some significant and new challenges on the clinical trials side in terms of staffing, infrastructure, those kinds of things. In that context, I made a decision to return to NIBR, refocus on clinical research, and hope to harness my background in running clinical trials in both settings, both academic and industry, as well as the resources and pipeline of Novartis to really maximize my impact on drug development. So for me, it was a question of where can I have the maximum impact at this crazy time, difficult time. I saw that my best option was to return to industry to work on studies to try to develop new therapies. Broadly speaking, my role as a senior clinical program leader in the translational and clinical oncology group at NIBR is to design, write, conduct, and analyze innovative clinical trials of early phase therapeutics.  Dr. Jeremy Cetnar: Wow, that's fascinating, very, very interesting. A lot of stress. You should definitely be buying lots of presents for your family for moving them all over the place.  This concludes part one of our interview with Drs. Abrey and Faris. Thank you so much for sharing your inspiring career stories. And thank you to all our listeners for tuning into this episode of the ASCO Education Cancer Topics podcast.  Thank you for listening to the ASCO Education podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center at education.asco.org.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

Is The Public Getting The Truth About Cancer? - Ralph Moss - Interview Ralph Moss • https://www.mossreports.com/• Book - Cancer, Incorporated and Immunotherapy: The Battle Within The medical writer Ralph W. Moss, PhD, has written or edited twelve books and four film documentaries on questions relating to cancer research and treatment.Dr. Moss is a graduate of New York University (BA, cum laude, Phi Beta Kappa, 1965) and Stanford University (MA, 1973, PhD, 1974, Classics). He is the former science writer and assistant director of public affairs at Memorial Sloan-Kettering Cancer Center in New York (1974-1977). Since leaving Sloan-Kettering in 1977, Moss has independently evaluated the claims of conventional and non-conventional cancer treatments all over the world. He currently writes Moss Reports, detailed reports on the most common cancer diagnoses and provides informational and personalized consultations for cancer patients and their families. In 2019, he wrote The Ultimate Guide to Cancer: DIY Research, to help lay people research their own cancers. This 50-page report is available free of charge at the mossreports.com website. #RalpMoss #TheRealTruthAbouthealth #Cancer #CancerTreament #CancerFightingFoods CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims.